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Abstract
English
In healthy subjects, glucose regulation relies on a complex hormonal con-
trol system that maintains the blood glucose level in a safe range. Impairment
of this regulatory system is the cause of several metabolic disorders, such as
type 1 diabetes (T1DM), characterized by the absolute deﬁciency of insulin
production, leading to a chronic hyperglycemia that, if not treated, can res-
ult in severe microvascular and macrovascular complications. Currently, the
best therapy for T1DM management makes use of a continuous subcutaneous
insulin pump (CSII) coupled with a subcutaneous continuous glucose mon-
itoring sensor (CGM), the so-called sensor-augmented-pump therapy (SAP).
Nevertheless, to ease T1DM subject's life condition, in the last decade, the
researchers have been focused on developing an automatic closed-loop con-
trol system for insulin infusion, the so-called Artiﬁcial Pancreas (AP), which
aims to maintain the glucose level within the euglycemic range.
In this regards, simulation models allowed important steps forward in the
AP research, enabling the possibility to perform several in silico tests, with
relevant time- and cost- savings. In particular, in 2008 the US Food and Drug
Administration accepted the T1DM simulator developed by Universities of
Virginia (UVA) and Padova as a substitute for preclinical trials for certain
insulin treatments, including closed-loop algorithms. This dramatically ac-
celerated the process for the approval of human trials. The UVA/Padova
simulator (S2008) is based on a rather complex model of glucose dynamics
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that was identiﬁed on a data set of 204 healthy subjects for which not only
plasma glucose and insulin measurements but also estimates of glucose ﬂuxes
were available. The simulator, equipped with 100 in silico adults, 100 adoles-
cents, and 100 children, spanning the variability observed in the real type
1 diabetic population, has been updated in 2013 in order to better describe
the distribution of glucose concentration observed in clinical trials (S2013).
However, at the beginning of this project, the simulator validity was never
been validated against clinical data. In addition, nowadays, the frontier of
the AP research is the development of control algorithm eﬀective for weekly
or monthly use. However, the T1DM simulator was not fully adequate for
the long-term testing, since its domain of validity was limited to a single-meal
scenario.
The ﬁrst aim of this research is thus to assess the simulator validity using
data of the available clinical trials. The second objective is to extend the do-
main of validity of the simulator, making it suitable for simulating long-term
clinical trials. Finally, a third scope is to illustrate the possible uses of the
simulator, including setting up a paradigm for in silico trials for testing of
new insulin treatments.
To achieve the ﬁrst objective, a database of 24 T1DM subjects was ﬁrst con-
sidered, who received dinner and breakfast in two occasions, for a total of
96 post-prandial glucose traces. Measured plasma glucose proﬁles were com-
pared with those obtained with both S2008 and S2013, by replicating in 100
in silico adults the same experimental condition of the data (i.e. same meal
amount and insulin delivery). The Continuous Glucose-Error Grid Analysis
was used to assess the validity of the simulated traces, and the most common
clinical outcome metrics, obtained in silico, were compared with the experi-
mental ones. The results were satisfactory, proving that the virtual adults of
the S2013 are representative of an age-matched T1DM population observed
in a clinical trial.
Then, the T1DM model has been validated on 47 T1DM subjects who re-
ceived dinner, breakfast and lunch, in three admissions, for a total of 23 hours
per session. In particular, given the complexity of the model and the avail-
ability of glucose and insulin measurements only, a Bayesian approach has
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been adopted for model identiﬁcation, considering, as a priori information,
the parameter distribution included in the simulator for the generation of in
silico subjects. Variability of model parameters describing glucose absorp-
tion and insulin sensitivity (SI, i.e. the ability of insulin to stimulate glucose
disposal and suppress endogenous glucose production) was allowed, assum-
ing that meal composition may be diﬀerent at breakfast, lunch, and dinner
(resulting in diﬀerent absorption rate), and that SI may vary throughout the
day. The model well described glucose traces and the posterior distribution
of model parameters was similar to that included in the simulator; absorption
parameters at breakfast were signiﬁcantly diﬀerent from those at lunch and
dinner, reﬂecting more rapid dynamics of glucose absorption; on the other
hand, insulin sensitivity varies in each individual but without a speciﬁc pat-
tern. These results suggested the need of a time-varying simulator to better
describe the glucose variability in the long-term.
In this regard, a model of intra-day variability of insulin sensitivity has been
developed, by using data of a recent multiple tracer experiment performed
in 20 T1DM subjects, which revealed the existence of diurnal patterns of SI,
with SI lower at breakfast than lunch and dinner, on average. This diﬀer-
ence was not statistically signiﬁcant, both due to the small population size
and the high inter-subject variability. In particular, seven SI daily patterns
were identiﬁed, and their probabilities were estimated from the data. This
information has been translated into the simulator by associating each in
silico subject to one of the seven variability patterns, and modeling its SI
with time-varying parameters. To test the goodness of the model, the same
experimental protocol of the 20 T1DM subjects was replicated in silico: the
comparison of simulated glucose against the data was satisfactory, showing
that the simulated plasma glucose level was higher at breakfast than lunch
and dinner, as the clinical data.
Finally, two case studies, illustrating the simulator employment, are presen-
ted. An AP adaptive control algorithm was tested ﬁrst. The performance
was evaluated in silico in a 1-month scenario: in particular, being able to
provide a realistic time-varying behavior of the system, it was possible to
prove evidence of the improved glucose control achievable with the adaptive
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control with respect to a non-adaptive AP algorithm. Then, the simulator
was employed to evaluate the pharmacological eﬀect of a novel inhaled in-
sulin: in particular, the simulator have served to evaluate the post-prandial
glucose in response to diﬀerent insulin dosing regimens, thus allowing to
determine, for each in silico subject, the best insulin pattern to optimally
control post-prandial glucose.
In conclusion, in this work, the UVA/Padova T1DM simulator was assessed
against clinical T1DM data; then, the T1DM model was identiﬁed on a
24-hour scenario, proving that a time-varying model was required to well de-
scribe the daily glucose variability; a model of intra-day variability of SI was
thus developed and incorporated into the simulator. Finally, the use of the
simulator was illustrated in two examples, i.e. the preclinical testing of an
adaptive AP algorithm and the design of optimal dosing regimen of a novel
inhaled insulin. In both cases, the simulator proved to be a useful tool for
the in silico testing of T1DM treatments.
ix
Italiano
Il metabolismo del glucosio nei soggetti sani è regolato da un complesso
sistema di controllo ormonale che mantiene la concentrazione plasmatica di
glucosio nel range di sicurezza. Alterazioni di tale sistema sono causa di di-
verse malattie metaboliche, tra cui il diabete mellito di tipo 1 (T1DM), una
malattia autoimmune che, a causa della totale incapacità del pancreas di se-
cernere insulina, è caratterizzata da una iperglicemia cronica che, se non trat-
tata, porta a complicanze cardiovascolari. Ad oggi, la miglior terapia per la
gestione del T1DM è la cosiddetta Sensor-Augmented-Pump, che impiega un
microinfusore di insulina (Continuous Subcutaneous Insulin Infusion, CSII)
e un sensore per la misura quasi continua della glicemia (Continuous Glu-
cose Monitoring, CGM), entrambi con accesso sottocutaneo. Tuttavia, allo
scopo di migliorare ulteriormente le condizioni di vita dei pazienti diabetici,
nell'ultimo decennio la ricerca si è orientata allo sviluppo del cosiddetto pan-
creas artiﬁciale (AP), ossia un sistema automatico di infusione di insulina,
atto a mantenere la glicemia il più possibile nel range euglicemico.
In questo contesto, i modelli di simulazione permettono di testare, velo-
cemente e in tutta sicurezza, le performance degli algoritmi di controllo in
diverse condizioni sperimentali. Tra questi, il simulatore di soggetti T1DM
sviluppato dalle Università di Padova e Virginia (UVA/Padova) è stato ac-
cettato nel 2008 dalla U.S. Food and Drug Administration come sostituto alla
sperimentazione preclinica animale per il test di trattamenti insulinici, tra cui
gli algoritmi di controllo utilizzati nel AP. Questo ha permesso di velocizzare
notevolmente il processo di approvazione alla sperimentazione nell'uomo. Il
simulatore UVA/Padova (S2008) si basa su un modello matematico del sis-
tema glucosio-insulina, che è stato identiﬁcato su un dataset di 204 soggetti
non diabetici, in cui erano a disposizione sia le misure plasmatiche di glucosio
e insulina che le stime dei ﬂussi metabolici di glucosio; esso è dotato inoltre
di una popolazione di soggetti virtuali, composta da 100 adulti, 100 adoles-
centi e 100 bambini, che rispecchia la variabilità di una popolazione diabetica
reale. Nel 2013, il simulatore è stato aggiornato (S2013) per migliorare la
descrizione della glicemia e renderla più simile a quella osservata nei trial
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clinici. Tuttavia, all'inizio di questo progetto, il simulatore non era ancora
stato validato su dati clinici. Inoltre, il limite di validità del simulatore era
vincolato a scenari tempo-invarianti, rendendolo, di fatto, poco adeguato al
test degli algoritmi di AP di ultima generazione, che mirano al controllo gli-
cemico nel lungo periodo.
Pertanto, lo scopo di questa tesi è innanzitutto validare il simulatore su
dati clinici di soggetti T1DM, e successivamente estendere il suo dominio di
validità a scenari tempo-varianti più realistici, permettendo quindi un test
più robusto degli algoritmi di AP nel lungo periodo. Inﬁne sono descritti due
esempi di applicazione del simulatore, tra cui il test in silico di insuline di
nuova generazione.
Per quanto riguarda il primo obbiettivo, è stato utilizzato un dataset di 96
tracce post-prandiali di glucosio, relative a 24 soggetti T1DM studiati in
due occasioni, a cena e colazione. Per validare il simulatore dal punto di
vista clinico, le popolazioni adulte di entrambe le versioni, S2008 e S2013,
sono state confrontate con quella reale, sottoponendo i soggetti in silico alle
stesse condizioni sperimentali dei soggetti reali (vale a dire stesse quantità di
carboidrati e insulina somministrati). Le glicemie simulate sono state quindi
confrontate con i dati utilizzando la Continuous Glucose-Error Grid Ana-
lysis e analizzando le più comuni metriche di quantiﬁcazione del controllo
glicemico. I risultati ottenuti hanno dimostrato che la popolazione adulta
della versione S2013 è rappresentativa di una popolazione T1DM adulta stu-
diata in un trial clinico.
Il modello del simulatore è stato successivamente validato su un dataset di 47
soggetti T1DM studiati in tre sessioni da 23 ore ciascuna, in cui venivano som-
ministrati tre pasti (cena, colazione, pranzo). Data la complessità del modello
e la disponibilità delle sole misure di glucosio e insulina, l'identiﬁcazione del
modello è stata eﬀettuata ricorrendo a un approccio di stima Bayesiano, in cui
l'informazione a priori utilizzata (prior) è la distribuzione congiunta dei para-
metri del modello utilizzata nel simulatore per la generazione dei soggetti in
silico. Per ottenere un buon ﬁt del modello, è stato necessario introdurre una
variabilità inter-individuale nei parametri che descrivono l'assorbimento del
glucosio legato al pasto e nella sensibilità insulinica (SI, un indice che quanti-
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ﬁca la capacità dell'insulina nell'inibire la produzione endogena di glucosio e
nel promuoverne l'utilizzazione da parte dei tessuti), ipotizzando l'esistenza
di variazioni relative alla composizione dei pasti tra colazione, pranzo e cena,
e variazioni di SI durante la giornata. I risultati hanno mostrato come il
modello sia in grado di descrivere le tracce glicemiche, e la distribuzione
delle stime dei parametri è risultata simile alla distribuzione inclusa nel sim-
ulatore. Come ci si attendeva, i parametri di assorbimento a colazione sono
risultati signiﬁcativamente diﬀerenti rispetto a quelli di pranzo e cena, de-
notando una dinamica di assorbimento più rapida a colazione; al contrario, i
risultati mostrano che la SI varia da un pasto all'altro, ma senza evidenziare
un pattern signiﬁcativo. Questi risultati hanno evidenziato che, per riuscire
a descrivere adeguatamente la variabilità glicemica durante la giornata, è
necessario un simulatore tempo-variante.
È stato quindi sviluppato un modello della variabilità diurna di SI, sfruttando
i risultati di un esperimento con traccianti multipli condotto in 20 soggetti
T1DM. In questo studio la SI stimata a colazione è risultata, in media, più
bassa rispetto alle stime di SI a pranzo e cena. Tale diﬀerenza, tuttavia,
non è risultata statisticamente signiﬁcativa a causa del modesto numero di
soggetti studiati e dell'alta variabilità inter-individuale. Pertanto, i soggetti
sono stati classiﬁcati in base ai valori di SI assunti durante la giornata; ciò
ha permesso di identiﬁcare sette classi di variabilità, ognuna caratterizzata
da una certa probabilità. Tale informazione è stata quindi implementata
nel simulatore, assegnando ogni soggetto in silico a una delle sette possibili
classi, e descrivendo quindi la SI del soggetto come un segnale che varia nel
tempo. Il modello di variabilità di SI è stato quindi validato simulando lo
stesso protocollo sperimentale dei dati e confrontando la variabilità glicemica
ottenuta in simulazione con quella osservata nei dati: in particolare, le sim-
ulazioni sono risultate confrontabili con i dati clinici, mostrando escursioni
post-prandiali a colazione più ampie rispetto a quelle osservate a pranzo e
cena.
Inﬁne, sono stati illustrati due esempi di utilizzo del simulatore. In un caso,
il simulatore è stato impiegato per il test in silico di un algoritmo di con-
trollo adattativo di AP. Nello speciﬁco, la performance di controllo è stata
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testata simulando uno scenario di un mese in cui, grazie all'integrazione del
modello di variabilità di SI, è stato possibile apprezzare come l'approccio
adattativo permetta un miglior controllo glicemico rispetto a un controllore
non adattativo. Nel secondo esempio, l'uso del simulatore ha permesso di
testare gli eﬀetti farmacologici di una nuova tipologia di insulina inalata: in
particolare, è stato possibile valutare l'escursione glicemica post-prandiale in
risposta a diversi regimi di somministrazione del farmaco, e determinare per
ogni soggetto virtuale il regime di somministrazione più adatto a garantire il
miglior controllo glicemico post-prandiale.
In conclusione, in questa tesi è stato innanzitutto validato il simulatore del
diabete di tipo 1 UVA/Padova utilizzando dati clinici di soggetti T1DM; suc-
cessivamente, il modello del simulatore è stato identiﬁcato su dati di soggetti
T1DM studiati in uno scenario di 24 ore, evidenziando la necessità di un
modello tempo-variante per descrivere correttamente l'andamento della gli-
cemia durante la giornata; il simulatore è stato quindi aggiornato, integrando
un modello di variabilità diurna di SI. Inﬁne, sono stati illustrati due casi di
studio, in cui il simulatore è stato impiegato per il test di un algoritmo di con-
trollo adattativo e per l'ottimizzazione del regime di somministrazione di una
nuova tipologia di insulina inalata. I risultati hanno dimostrato l'utilità del
simulatore UVA/Padova per il test di trattamenti terapeutici per la gestione
del diabete.
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1
Introduction
1.1 Background
1.1.1 Glucose metabolism and diabetes
It is crucial that blood glucose level does not decrease under 70 mg/dL
since glucose is the predominant metabolic fuel for the brain which cannot
store more than a few minutes supply as glycogen, or quickly increase its ex-
traction of glucose from the circulation. The glucose concentration in blood
is thus regulated by a complex internal feedback systems that keep blood glu-
cose level within a narrow range around its basal value (target blood glucose
range: 70 − 180 mg/dL). Hypoglycemia is identiﬁed when plasma glucose
concentration goes below 70 mg/dL, while hyperglycemia occurs when glu-
cose concentration raises over 180 mg/dL [99]. Prevention of hypoglycemia
is critical to survival. On the other hand, the chronic hyperglycemia leads to
micro- and macro-vascular complications which include limb loss, blindness,
ischemic heart disease, and end-stage renal disease [99101].
Comprehension of the mechanisms that regulate plasma glucose have signiﬁc-
antly evolved since the discovery in the 1920s of the peptide hormone insulin,
which was considered the main responsible of glucose homeostasis. Insulin
is secreted by β-cells in the islets of Langerhans in response to high levels of
plasma glucose, promotes the glucose utilization by tissues and inhibits the
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endogenous glucose production by liver and kidney. In the 1950s pancreatic
α-cells hormone glucagon was discovered. It is secreted in response to a fall
in plasma glucose concentration below the hypoglycemic threshold, and acts
by stimulating hepatic glycogenolysis and gluconeogenesis, thus raising en-
dogenous glucose production and resulting in an increase of plasma glucose
concentration. Then, other hormones have been discovered to contribute to
glucose regulation, such as amylin, incretin hormones (e.g. GLP1), growth
hormone, epinephrine, and cortisol, although their eﬀects is modest if com-
pared with insulin and glucagon (Figure 1.1). In these regards, the glucose
regulation can be meant as a bi-hormonal system, with insulin represent-
ing the key regulatory hormone of glucose disappearance, and glucagon the
major regulator of endogenous glucose release.
Incretin 
Glucagon 
Insulin 
Amylin 
Beta-Cell 
Alpha-Cell 
Gastring Emptying 
Glucose Rate of Appearance 
GlucoseRate of 
Disappearance 
L-Cell 
Glucagon Secretion 
Glucose 
Cortisol 
Epynephrine 
GH 
Figure 1.1: Glucose homeostasis in healthy individuals: roles of the major
hormones. Black lines represent ﬂuxes, red dotted lines represent inhibition control
signals and green dotted lines represent promotion control signals.
Impairment of the glucose regulatory system is the cause of several meta-
bolic disorders, such as diabetes. Diabetes is a chronic disease, characterized
by the inability of the body to well control the blood glucose concentration,
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mainly due to a total deﬁciency in insulin secretion (type 1 diabetes, T1DM)
or to both an impairment in insulin action and the inability of β-cells to
compensate for that (type 2 diabetes, T2DM), which lead to a chronic hy-
perglycemia. In particular, type 1 diabetes is the result of immune-mediated
destruction of the pancreatic β-cells, i.e. the site of insulin production and
secretion. Despite T1DM represents about only the 5%-10% percent of the
world diabetic population (while the remaining 90% is T2DM), it has a strong
impact on patient's life: it usually occurs in childhood and adolescence (al-
though it can occur at all ages), and, due to the absolute insulin deﬁciency,
the insulin therapy to control hyperglycemia is required for the entire life.
1.1.2 Diabetes treatments
Since its discovery in the 1920s, insulin has been the only pharmaco-
logical treatment usable for the T1DM management. Advances in insulin
therapy have included not only improving the source and purity of the hor-
mone, but also developing more physiological means of delivery, from the
ﬁrst auto syringe to the more sophisticated insulin pump, i.e. the continuous
subcutaneous insulin infusion (CSII) systems [38, 61, 72, 103]. Paralleling,
technological advances in glucose measurement devices allowed to pass from
the ﬁrst portable glucometers in the 1970s, rather bulky and cumbersome, to
the recent subcutaneous continuous glucose monitoring (CGM) systems, i.e.
minimally invasive glucose sensors which provide the glucose levels almost in
real-time [29, 41, 88].
Nowadays, the best approach to the T1DM management is the so-called
sensor-augmented-pump therapy (SAP), which makes use of a subcutaneous
insulin pump coupled with a CGM sensor. Several clinical studies have
demonstrated the impact of SAP therapy in glucose control, with beneﬁts
for patients' life, e.g. [5, 81, 83]. Nevertheless, a lot of actions are still left
to subject's self management, which deﬁnitely aﬀect his life condition. For
example, a single meal involves the estimation of carbohydrate content, the
measurement of pre-prandial glycemia, the calculation and injection of the
insulin meal bolus, and, if needed, the calculation and administration of a
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post-prandial correction bolus.
Thus, in order to improve patients' life condition, recently the research
addressed its eﬀorts on the development of the so-called Artiﬁcial Pancreas
(AP), i.e. an automated system combining a glucose sensor, a closed-loop
control algorithm, and an insulin infusion device. AP research has been
active for the last 50 years: after the pioneering work by Kadish [39] in 1964,
there were some works reporting closed-loop control results between 1974
and 1978, [1, 52, 62, 71, 82], with the commercialization, in the 1977, of
the ﬁrst AP device, i.e. the Biostator [11]. However, the hardware setup
consisted of glucose sensors and insulin infusion systems with intravenous
access, thus being not suitable for the use in daily life. It is right thanks to the
recent introduction of CGM and CSII systems and the incorporation of AP
control algorithm into portable platforms that it was possible to perform an
increasing number of clinical trials, moving from an inpatient to an more real-
life-resambling outpatient setup, with experiments lasting some days [8, 17,
25, 27, 28, 49, 54, 77]. Examples of AP systems diﬀerent hardware technology
are shown in Figure 1.2.
Figure 1.2: Technology evolution in AP research: the Biostator [11] (Left panel);
a portable AP in 2010s, i.e. Diabetes Assistant (DiAs) [40] (Right panel).
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However, despite the technological improvements of the hardware setup,
there are several drawbacks related to the closed-loop controllers that need to
be enhanced, such as the therapy optimization during particular conditions
(like physical exercise) or the meal bolus management. Moreover, it is worth
noting that the current employed rapid acting insulin analogs are suitable for
the insulin basal daily coverage, but represent the bottleneck for the optimal
meal control: in fact, the rapid rise of postmeal glucose is diﬃcult to avert
because of the inherent delays in subcutaneous insulin absorption and action
[87]. Hence, alterative routes of insulin administration, such has intradermal,
intraperitoneal and pulmonary, are currently under study.
1.1.3 Simulation models
Simulation models allowed important steps forward in testing the per-
formance of AP algorithms or diﬀerent insulin infusion routes, enabling the
possibility to perform several in silico tests, with relevant time- and cost-
saving. Simulation models are widely employed in physics and engineering,
where system structure and behavior are generally known, and thus the dy-
namics can be mathematically represented by using ﬁrst principles. These
powerful tools are used whenever a certain system results too diﬃcult, ex-
pensive, dangerous, unethical or impossible to reproduce in a laboratory.
In the last 40 years, several simulation models of the glucose system have
been developed, e.g. [2, 14, 15, 18, 31, 56, 78, 84, 86]. However, the im-
pact of these models in the AP research was modest: these old generation
simulators, despite providing a detailed description of the system, are based
on average models, i.e. they are able to describe only the average dynam-
ics of the system in a populations, but not the inter-individual variability,
which actually is crucial to perform realistic in silico trials and appropriately
test the robustness of control algorithms. In addition, the old generation
simulators were all based on plasma glucose and insulin concentrations only,
and given model complexity, such information is not suﬃcient to properly
describe the system.
6 Introduction
In the last decade, new generation T1DM simulators have been developed,
aiming to reproduce inter-subject variability of glucose dynamics in a type
1 diabetic population. Among them, a simulator environment has been pro-
posed by the Cambridge group, which is based on a high order model of
glucose dynamic that was identiﬁed on glucose and insulin data of T1DM
subjects monitored in a clinical trial [35]. Given the large number of model
parameters, some of them have been ﬁxed to population values available in
the literature [36, 37, 57], in order to make the model identiﬁable. However,
being the model identiﬁed on plasma glucose and insulin concentrations, the
compensation among the parameters was very likely.
The UVA/Padova T1DM simulator
A diﬀerent approach was employed in developing the T1DM simulator
proposed by the University of Padova in collaboration with the University of
Virginia (UVA) [43],[20]. In particular, the UVA/Padova T1DM simulator
is based on a rather complex model of glucose dynamics that was identiﬁed
using not only plasma glucose and insulin measurements but also estimates
of the glucose ﬂuxes, i.e. plasma glucose rate of appearance after a meal
(Rameal), endogenous glucose production (EGP ) by liver and kidney, glu-
cose utilization (U) by tissues, available in a large population of healthy
subjects studied with multiple tracer [3]. This represents the peculiarity
of the UVA/Padova T1DM simulator, that allowed to generate 100 in silico
adults, 100 adolescents, and 100 children, which span the variability observed
in the real type 1 diabetic populations. More details on model developments
are provided in Chapter 2.
A ﬁrst version of the simulator was proposed in 2008 (S2008, [43]), and was
accepted by the U.S. Food and Drug Administration (FDA) as a substitute
for preclinical trials for certain insulin treatments, including closed-loop con-
trol algorithms. In these years, the simulator has been extensively used by
several institutions, academies and pharmaceutical companies. In 2013, the
simulator was updated (S2013), in order to account for counteregulation sys-
tem and include a better description of glucose dynamics in hypoglycemia
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[20].
At the beginning of this project, despite the improvements introduced
in the last version, the UVA/Padova T1DM simulator still presented some
limitations. First of all, it was never been validated against a T1DM popu-
lation, despite this step was required to evaluate whether the simulator was
representative of real T1DM subjects, since, as it will be explained in Chapter
2.2.2, its model was based on a dataset of healthy subjects [3].
Another important point to take into account is that the simulator was time-
invariant: in fact, being it developed on single meal data [3], the simulator
was unable to describe glucose variations that can occur in a day. In this
regard, with the increasing outpatient long-term clinical trials [53, 55], the
need to extend the domain of validity of the simulator has become crucial,
in order to improve the ability of the simulator to predict glucose variability
in the long period, thus providing more realistic scenarios for long-term in
silico trials. Once these limitations are overcome, the simulator can be an
useful tool not only in AP context but also for testing new insulin molecules
and diﬀerent insulin delivery routes.
1.2 Aim
The aim of this thesis is to overcome the limitations of the UVA/Padova
T1DM simulator described above, thus making it a suitable framework for
the in silico testing of AP control algorithms and new T1DM treatments. To
achieve this goal one has:
• To assess the simulator validity against T1DM data of the now available
clinical trials.
• To develop an intra-subject variability model to extend the domain of
validity of the simulator, thus making the simulator suitable for long-
term AP clinical trials.
• To show examples of simulation use, for testing both AP controllers
and novel insulin treatments.
8 Introduction
1.3 Outline of the thesis
The thesis is articulated as follows:
Chapter 2 presents an overview on the UVA/Padova T1DM simulator, illus-
trating its main characteristics, the improvements introduced with the 2013
update, and the main drawbacks that motivated the present research.
Chapter 3 describes the experimental data used to develop and validate the
model.
Chapter 4 describes the methodology carried out to clinically assess the sim-
ulator against a T1DM population observed during a clinical trial.
Chapter 5 describes the approach adopted to validate the model of the T1DM
simulator on a large T1DM population studied on a 24-hour scenario. This
will highlight the need of a time-varying simulator in order to well describe
the glucose variability in the long-term.
Chapter 6 presents a model of intra-day variability of insulin sensitivity to
be incorporated into the simulator, in order to improve the description of
diurnal glucose variability. This will provide a new time-varying simulator.
Chapter 7 presents two applications of the simulator: i) for testing an ad-
aptive control algorithm; ii) for assessing the best dosing of a novel insulin
treatment.
Speciﬁc comments are reported at the end of Chapters 4−6. The results
obtained in this work as well as emerged open questions and future research
directions are discussed in Chapter 8.
2
The UVA/Padova T1DM simulator
2.1 Introduction
In this chapter, a detailed description of the UVA/Padova T1DM Simu-
lator is provided. The ﬁrst version of the simulator (S2008) [43], accepted in
2008 by FDA as a substitute to animal trials for the preclinical testing of con-
trol strategies in artiﬁcial pancreas studies [42], is presented ﬁrst. Then, the
modiﬁcations introduced in 2013 (S2013) to ﬁx some of the main drowbacks
of S2008, are described.
2.2 T1DM simulator 2008
The original version of the UVA/Padova T1DM Simulator (S2008) con-
sists of a model of glucose-insulin dynamics during a meal, a population of
300 virtual patients and an user interface.
2.2.1 The model
The matematical model describing glucose dynamics in T1DM subjects
derives from a model built on data of healthy subjects (as explained below).
In fact, model structure is the same in healty and T1DM except for some
equations. Thus, the model of healthy subject is presented ﬁrst, then the
modiﬁcation needed to simulate T1DM subjects are introduced.
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Healthy model
The model of healthy subject, schematically shown in Figure 2.1 (upper
panel), was proposed by Dalla Man and colleagues in 2007 [22]. Brieﬂy, the
model assumes that the glucose and insulin subsystems are linked one to
each other by the action of insulin on glucose utilization and endogenous
production, and the control of glucose on insulin secretion by the β-cells.
The glucose subsystem consists of a two-compartment model describing
glucose kinetics [93]:
G˙p(t) = EGP (t) +Rameal(t)−Uii(t)− E(t)− k1·Gp(t) + k2·Gpt(t)
Gp(0) = Gpb
G˙t(t) = −Uid(t) + k1·Gp(t)− k2·Gpt(t)
Gt(0) = Gtb
G(t) = Gp(t)/VG
G(0) = Gb
(2.1)
where Gp and Gp (mg/kg) are glucose masses in plasma and rapidly equilib-
rating tissues, and in slowly equilibrating tissues, respectively; G (mg/dL) is
the plasma glucose concentration; suﬃx b denotes basal state; EGP is the
endogenous glucose production (mg/kg/min); Rameal is the glucose rate of
appearance in plasma (mg/kg/min); E is renal excretion (mg/kg/min); Uii
and Uid (mg/kg/min) are the insulin-independent and -dependent glucose
utilizations, respectively; VG is the distribution volume of glucose (dL/kg);
and k1 and k2 are the rate parameters.
The insulin subsystem also consists of two compartments, describing the
insulin in the liver and the plasma [30]:
I˙p(t) = −(m2 +m4)·Ip(t) +m1·Il(t) + S(t)
Ip(0) = Ipb
I˙l(t) = −(m1 +m3)·Il(t) +m2·Ip(t)
Il(0) = Ilb
I(t) = Ip(t)/VI
I(0) = Ib
(2.2)
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Figure 2.1: Scheme of the glucose-insulin model in healthy (upper panel), and
model of S2008 T1DM simulator (lower panel). In the latter, endogenous insulin
secretion is replaced by an exogenous insulin administration.
where Il and Ip (pmol/kg) are insulin masses in plasma and in liver, respect-
ively; I (pmol/L) is the plasma insulin concentration; suﬃx b denotes basal
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state; S is the insulin secretion (pmol/kg/min); VI is the distribution volume
of insulin (L/kg); m1, m2 (min−1) are rate parameters; ﬁnally, degradation
(D) occurs both in the liver (through m3) and in the periphery (linearly
through m4). Hepatic insulin extraction (HE), i.e. the insulin ﬂux leaving
the liver irreversibly divided by the total insulin ﬂux leaving the liver, is time
varying, depending on S:
HE(t) = −m5·S(t) +m6 HE(0) = HEb (2.3)
so that
m3(t) =
HE(t)
1−HE(t) ·m1 (2.4)
Parameters m2 and m4 are derived from equation (2.2) at basal state and
considering that the liver is responsible for 60% of insulin clearance in the
steady state:
m2 =
(
Sb
Ipb
− m4
1−HEb
)
·1−HEb
HEb
(2.5)
m4 =
2
5
· Sb
Ipb
(2.6)
where Sb is the basal insulin secretion, and HEb is assumed ﬁxed to 0.6.
Endogenous glucose production, glucose rate of appearance, and glucose
utilization are the most important model unit processes. Suppression of EGP
(mg/kg/min) is assumed to be linearly dependent on plasma glucose mass
and a delayed insulin action on the liver (XL) [23]:
EGP (t) = kp1 − kp2·Gp(t)− kp3·XL(t) EGP = EGPb (2.7)
X˙L(t) = −ki · [XL(t)− I ′(t)] XL(0) = Ib (2.8)
I˙ ′(t) = −ki · [I ′(t)− I(t)] I ′(0) = Ib (2.9)
where XL is obtained with a chain of two compartments; kp1 (mg/kg/min)
is the extrapolated EGP at zero glucose and insulin, kp2 (min−1) is the liver
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glucose eﬀectiveness, kp3 (mg/kg/min per pmol/L) is a parameter governing
amplitude of insulin action on the liver (i.e. the insulin sensitivity on glucose
prouction), and ki is the rate parameter accounting for delay between insulin
signal and insulin action.
Glucose intestinal absorption describes the glucose transit through the
stomach and intestine by assuming the stomach to be represented by two
compartments (one for solid and one for liquid phase), while a single com-
partment is used to describe the gut [19]:
Qsto(t) = Qsto1(t) +Qsto2(t)
Qsto(0) = 0
Q˙sto1(t) = −kgri·Qsto1(t) +D·δ(t)
Qsto1(0) = 0
Q˙sto2(t) = −kempt(Qsto)·Qsto2(t) + kgri·Qsto1(t)
Qsto2(0) = 0
Q˙gut(t) = kabs·Qgut(t) + kempt(Qsto)·Qsto2(t)
Qgut(0) = 0
Rameal(t) =
f ·kabs·Qgut(t)
BW
Rameal(0) = 0
(2.10)
with Qsto (mg) the amount of glucose in the stomach (solid, Qsto1 and liquid
phase Qsto2), and Qgut (mg) the glucose mass in the intestine; kgri is the rate
of grinding; kempt is the rate constant of gastric emptying, described as a
nonlinear function of Qsto:
kempt(Qsto) = kmin +
kmax − kmin
2
·
· {tanh[α(Qsto − β·D)]− tanh[β(Qsto − c·D)] + 2} (2.11)
kabs is the rate constant of intestinal absorption; f is the fraction of intest-
inal absorption which actually appears in plasma; D (mg) is the amount of
ingested glucose; BW (kg) is the body weight.
Glucose utilization U is based on the literature [63, 75, 76, 102], and is
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the sum of two terms: a constant insulin-independent utilization (Uii), which
takes place in the ﬁrst compartment, representing glucose uptake by the brain
and erythrocytes (Fcns), and an insulin-dependent utilization (Uid), which oc-
curs in a remote compartment, representing peripheral tissues and depending
nonlinearly (as Michaelis-Menten) from glucose in the tissues [102]:
Uii(t) = Fcns (2.12)
Uid(t) =
[Vm0 + Vmx·X(t)] ·G(t)
Km0 +Gt(t)
(2.13)
X˙(t) = −p2U ·X(t) + p2U ·[I(t)− Ib] X(0) = 0 (2.14)
where Vmx (mg/kg/min per pmol/L) and X (pmol/L) are, respectively, the
insulin sensitivity and the insulin action on glucose utilization; p2U is the rate
constant of insulin action on the peripheral glucose utilization.
Glucose renal excretion (E) by the kidney occurs if plasma glucose ex-
ceeds a certain threshold and can be modeled by a linear relationship with
plasma glucose:
E(t) =
ke1·[Gp(t)− ke2] if Gp(t) > ke20 if Gp(t) ≤ ke2 (2.15)
where ke1 (min−1) is the glomerular ﬁltration rate and ke2 (mg/dL) is the
renal threshold of glucose.
Insulin secretion (S) by β-cells is described by a model proposed by
Toﬀolo and colleagues [91]:
S(t) = γ·Ipo(t) (2.16)
I˙po(t) = −γ·Ipo(t) + Spo(t) Ipo(t) = Ipob (2.17)
S˙po(t) =
Y (t) +K·G˙(t) + Sb for G˙(t) > 0Y (t) + Sb for G˙(t) ≤ 0 (2.18)
Y˙po(t) =
−α·
[
Y (t)− β·(G(t)− h)] if β·(G(t)− h) ≥ −Sb
−α·[Y (t) + Sb] if β·(G(t)− h) < −Sb Y (0) = 0
(2.19)
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where γ (min−1) is the transfer rate constant between portal vein and liver,
K (pmol/kg per mg/dL) is the pancreatic responsivity to the glucose rate of
change, α (min−1) is the delay between glucose signal and insulin secretion,
β (pmol/kg/min per mg/dL) is the pancreatic responsivity to glucose, and
h (mg/dL), set to Gb to guarantee system steady state in basal condition, is
the threshold level of glucose above which the β-cells secrete new insulin.
T1DM model
As already discussed in Chapter 1.1.1, in T1DM subjects an external
insulin ifusion is required to supply the deﬁciency in β-cell insulin secretion.
Thus, in the model of the T1DM subject, insulin secretion is replaced by
a model of external insulin delivery (Figure 2.1, lower panel). In particu-
lar, subcutaneous insulin kinetics is described as a variation of the model
proposed in [64] 
I˙sc1(t) = −(kd + ka1)·Isc1(t) + IIR(t)
Isc1(0) = Isc1ss
I˙sc2(t) = kd·Isc1(t)− ka2·Isc2(t)
Isc2(0) = Isc2ss
(2.20)
where Isc1 is the amount of nonmonomeric insulin in the subcutaneous space,
Isc2 is the amount of monomeric insulin in the subcutaneous space, IIR
(pmol/kg/min) is the exogenous insulin infusion rate, kd (min−1) is the rate
constant of insulin dissociation, and ka1 and ka2 are the rate constants of non-
monomeric and monomeric insulin absorption, respectively. Thus, equation
(2.2) becomes
I˙p(t) = −(m2 +m4)·Ip(t) +m1·Il(t) +RaI(t)
Ip(0) = Ipb
I˙l(t) = −(m1 +m3)·Il(t) +m2·Ip(t)
Il(0) = Ilb
I(t) = Ip(t)/VI
I(0) = Ib
(2.21)
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where RaI is the rate of appearance of external insulin in plasma
RaI(t) = ka1·Isc1(t) + ka2·Isc2(t) (2.22)
The T1DM model of equations (2.1), (2.3)-(2.15), (2.21), (2.22), has 26
free parameters, among which the most important are hepatic and peripheral
insulin sensitivity (kp3, Vmx), representing the ability of plasma insulin to in-
hibit endogenous glucose production and enhance glucose disposal, respect-
ively.
2.2.2 Identiﬁcation strategy and joint parameters dis-
tribution
As already stated in Chapter 1.1.3, the key strength of the UVA/Padova
simulator is the availability of a robust joint distribution of model parameters,
i.e. the covariance matrix used for the generation of the in silico subjects. In
other words, a reliable correlation among the model parameters allows to well
describe the inter-subject variability without the risk of compensation among
the model parameters. This was achievable by identify the simulation model
on both plasma glucose and insulin concentrations and estimates of post-
prandial ﬂuxes, i.e. Rameal, EGP , U , and, in healthy subjects, S. However,
at the time of simulator conception, such information was available uniquely
in a large non-diabetic population [3], in which 204 subjects underwent a
triple-tracer mixed meal study. Brieﬂy, this technique [4] is able to minimize
ﬂuctuations in tracer-to-tracee ratio, allowing an accurate measurement of
glucose turnover. In particular, in [3], one oral tracer was added to the meal,
while two other tracers were intravenously infused to mimic, respectively,
the expected Rameal and EGP time courses; the estimation of U was then
obtained from glucose rate of change through principles of mass balance;
ﬁnally, S was reconstructed by deconvolution [73].
The model of equations (2.1)-(2.19) [22] was thus identiﬁed on this avail-
able data by decomposing the model into its single processes and using a
forcing functions strategy, as illustrated in Figure 2.2. Unit process mod-
els were identiﬁed for each subject, thus providing the distribution of model
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Figure 2.2: Unit process models and forcing function strategy: EGP (top left
panel); Rameal (top right panel); U (bottom left panel); S (bottom right panel).
Entering arrows represent forcing function variables, outgoing arrows are model
output.
parameter estimates in the population. Both the average vector and the co-
variance matrix were calculated from the parameter estimates, thus deﬁning
the joint distribution of model parameters. The rationale is illustrated in
Figure 2.3. It is worth noting that model parameters describing insulin se-
cretion are substituted by kd, ka1 and ka2 (appearing in equations (2.20) and
(2.22)), which are assumed uncorrelated from the other model parameters,
since they are not estimated but ﬁxed to population values taken from the
literature [21]. This is not in contrast with the physiology of the system (sub-
cutaneous insulin absorption in T1DM, at variance with insulin secretion in
healthy, is independent on subject's insulin sensitivity or other parameters
determining glucose control).
2.2.3 In silico populations
The in silico T1DM population is made up of 100 adults, 100 adolescents,
and 100 children. Each in silico subject is represented by a vector containing
subject-speciﬁc model parameters, which has been generated by randomly
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period until the last years. Now that AP algorithms are tested in long-term
trials, preclinical phase havs to be appropriate, thus the simulator has to
be able to well describe the possible variations that can occur during the
day. In other words, to better describe the physiology, the simulator must
be time-varying (Figure 1.4).
Figure 1.4: Comparison of a time-invariant (red line) vs. a time-varying (green
line) simulation scenario, obtained in an illustrative subject undergoing three
identical meals. As it can be observed, with the current simulator the glucose dy-
namic exhibits the same pattern during the day. On the contrary, a time varying
simulator would allow the introduction of a certain glycemic variability, similarly
to what occurs in real life.
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Figure 2.3: Scheme of the procedure used to generate the joint parameter dis-
tribution: the identiﬁcation of all the unit processes provide a vector of model
parameters for each subject; the set of all parameter vectors constitutes the para-
meter distribution, from which both the average vector and the covariance matrix
are extracted.
extracting one realization of the model parameter vector from the parameter
joint distribution described above.
In addition to the model parameters, to each virtual subject is associated an
optimal insulin therapy, described by three key parameters: the carbohydrate-
to-insulin ratio (CR), the insulin basal rate, the total daily insulin (TDI), and
the insulin correction factor (CF). CR (g/U) determines the amount of insulin
required to cover the charbohydrates (CHO) contained into a certain meal.
It is calculated as the largest bolus in insulin units per grams of CHO that
does not create a drop in plasma glucose lower than 95% of fasting plasma
glucose after a meal containing 50 g of CHO. Insulin basal rate (U/hr) is the
rate of insulin infusion required to maintain the subject at basal state during
fasting conditions. TDI is computed based on a 200 g CHO daily diet, using
a basal insulin infusion rate maintaining fasting glucose and the CHO ratio.
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2.3 T1DM simulator 2013
The updated version of the UVA/Padova T1DM simulator (S2013) pre-
sents some important improvements with respect to S2008, both on the model
on which the simulator is based, but also on the joint parameter distribution,
the deﬁnition of clinically relevant parameters, and the strategy for in silico
subjects generation.
2.3.1 Model improvements
With respect to the previous version, S013 model, showed in Figure 2.4,
includes some modiﬁcations. A model of glucagon kinetics, secretion, and
action, is added in order to account for counterregulation. In particular,
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Figure 2.4: Scheme of the S2013 T1DM simulator.
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glucagon kinetic consists of a single-compartment model:
H˙(t) = −n·H(t) + SRH(t) H(0) = Hb (2.23)
where H (ng/L) is the plasma glucagon concentration; suﬃx b denotes basal
state; SRH (ng/L/min) is the glucagon secretion; and n (min−1) is the clear-
ance rate. Glucagon secretion is described as the sum of two components,
i.e. one static and one dynamic:
SRH(t) = SR
s
H(t) + SR
d
H(t) (2.24)
Static secrection (SRsH , ng/L/min) is described as follows:
˙SR
s
H(t) =

−ρ·[SRsH(t)−max(σ2[Gth−G(t)]+SRbH , 0)] if G(t) ≥ Gb
−ρ·
[
SRsH(t)−max
(
σ[Gth−G(t)]
I(t)+1
+SRbH , 0
)]
if G(t) < Gb
(2.25)
where G and I are the plasma glucose and insulin concentrations; suﬃx
b denotes basal state; σ and σ2 (ng/L/min per mg/dL·L/pmol) are α-cell
responsivities to glucose level, ρ (min−1) is the rate parameter accounting
for the delay between static glucagon secretion and plasma glucose. In this
way, static secretion is stimulated when G < Gb (but modulated by insulin)
and inhibited when G ≥ Gb. On the other hand, dynamic secretion (SRdH ,
ng/L/min) is related to the glucose rate of change:
SRdH(t) = δ·max
(
−dG(t)
dt
, 0
)
(2.26)
where δ (ng/L·mg/dL) is the α-cell responsivity to glucose rate of change.
It is worth noting that, in real life, glucagon secretion is almost certainly
dependent on insulin level in the α-cells (paracrine eﬀect), not in the circu-
lation. However, due to the diﬃculty to model the intrapancreatic levels,
the use of plasma insulin, even if not perfectly physiologic, appears the the
best surrogate. The model of EGP has been updated, so that equation (2.7)
becomes:
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EGP (t) = kp1−kp2·Gp(t)−kp3·XL(t)+ξ·XH(t) EGP = EGPb (2.27)
X˙H(t) = −kH ·XH(t)+kH ·max[(H(t)−Hb), 0] XH(0) = 0 (2.28)
where XH (ng/L) is the delayed glucagon action on EGP , ξ (mg/kg/min
per ng/L) is the liver responsivity to glucagon, and kH (min−1) is the rate
parameter accounting for the delay between glucagon concentration and ac-
tion.
Another important change in the simulator model concerns the descrip-
tion of glucose dynamics in hypoglycemia. In fact, the model of glucose
utilization of equations 2.13 and 2.14 is unable to well describe the hypogly-
cemic range likely due to an inadequate description of insulin action, which
paradoxically increases when glucose decreases under a certain threshold.
This phenomenon has been described during hyperinsulemic clamps in T1DM
[47, 51]. Based on this observation, a new model has been developed, which
assumes that insulin-dependent utilization Uid increases when glucose de-
creases below a certain threshold, following the blood glucose risk function
[50]:
Uid(t) =
[Vm0 + Vmx·X(t)·(1 + r1·risk)]·G(t)
Km0 +Gt(t)
(2.29)
risk =

0 if G ≥ Gb
10·[f(G)]2 if Gth ≤ G < Gb
10·[f(Gth)]2 if G < Gth
(2.30)
f(G) = log
(
G
Gb
)r2
(2.31)
where Gb is the basal glucose, Gth is the hypoglycemic threshold (set at 60
mg/dL), and r1 and r2 are risk model parameters.
2.3.2 New joint distribution of model parameters
The incorporation of glucagon model into the simulator required also to
update the parameter joint distribution. In particular, a diﬀerent database
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was considered [76], in which non-diabetic subjects received an intraven-
ous insulin bolus with the aim to bring them in hypoglycemia (usually not
achievable in healthy under physiological conditions), and EGP was estim-
ated using a procedure similar to that described in Chapter 2.2.2. It is to note
that covariance matrix related to counterregulation was added to the original
one of S2008, maintaining them uncorrelated, since they were generated from
diﬀerent datasets.
2.3.3 New in silico population
The generation of model parameters was performed paralleling what de-
scribed in Chapter 2.2.3. Some reﬁnements have been introduced in the
calculation of relevant clinical parameters. In particular, at variance with
S2008, CR was determined with the following simulation, which mimics, as
much as possible, the criterion used to empirically determine it in real pa-
tients: each subject receives 50 g of CHO, starting from his basal level. The
optimal insulin bolus is determined so that: (1) glucose concentration, meas-
ured 3 hours after the meal, is between 85% and 110% of its basal level; (2)
the minimum glucose concentration is above 90 mg/dL; and (3) the max-
imum glucose concentration is between 40 and 80 mg/dL above the basal
level. CR is then calculated as the ratio between the amount of ingested
CHO and the optimal insulin bolus:
CR =
ingested CHO
optimal bolus
(2.32)
CF was determined with the so-called 1700 rule [24],
CF =
1700
TDI
(2.33)
where TDI is the total daily insulin, determined for each virtual patient,
using optimal CR and basal infusion rate, and assuming an average diet of
180 g of CHO for adolescents and adults and 135 g of CHO for children.
Finally, also new criteria for the generation of the in silico subjects have
been introduced. In particular: (1) CR ≤ 30 g/U for adult and adolescents
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and CR ≤ 40 g/U for children; (2) steady state glucose in absence of insulin
infusion > 300 mg/dL; and (3) Mahalanobis distance [65] lower than that
corresponding to the 95% percentile.
2.4 Limitations of S2013
As already stated at the end of Chapter 1.1.3, even though the UVA/Padova
T1DM simulator was largely used for the in silico testing of AP algoritms,
when the present research started, there were some criticisms that had to be
addressed.
First of all, as described in Chapter 2.2.2, the simulator core was not directly
derived from T1DM data, i.e. the parameter joint distribution was extracted
from non-diabetic individuals [3]; in this regard, Chapters 4 and 5 describe
the validation of the simulator against T1DM populations observed in clin-
ical trials.
Secondly, the simulator was developed on single meal data. So far, AP con-
trollers have been successfully tested in the short period, so that this did not
represent a big issue. Nevertheless, at the beginning of this thesis, the AP
research envisioned the possibility to extend AP testing in long-term trials
− and, indeed, it was recently achieved, as described in [53, 55]. Hence, the
simulator has to be able to well describe the possible variations that can occur
during the day, in order to provide an appropriate test bed for the preclinical
phase. In other words, to better describe the physiology, the simulator must
be time-varying (Figure 2.5).
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Figure 2.5: Comparison of a time-invariant (red line) vs. a time-varying (green
line) simulation scenario, obtained in an illustrative subject undergoing three
identical meals. As it can be observed, with the current time-invariant simulator
the glucose dynamic exhibits the same pattern during the day. On the contrary, a
time-varying simulator would allow the introduction of a certain glycemic variabil-
ity, similarly to what occurs in real life.

3
Databases and protocols
3.1 Introduction
In this chapter the data bases and protocols used in this work are de-
scribed.
In particular, three diﬀerent datasets have been used, each one having the
characteristics needed for a particular purpose: Database1 is employed for
the clinical assessment of the state-of-art simulator (Chapter 4); Database2
is employed for model validation (Chapter 5); Database3 is used to develop
the intra-subject variability model (Chapter 6).
3.2 Database 1
The database used for model assessment consists of 24 T1DM adult sub-
jects (14 males, age = 42.8±11.9 years, BW = 74.8±13.6 kg) [44], recruited at
the Universities of Virginia, Charlottesville (N = 11), Padova, Italy (N = 7),
and Montpellier, France (N = 6).
Each patient had two 22-hour hospital admissions (from 3:00 p.m. to 1:00
p.m. on the following day), one in open- and one in closed-loop, respect-
ively. During the open-loop session, the subject-speciﬁc basal-bolus therapy
was used with the personal insulin pump. During the closed-loop session, an
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OmniPodR© Insulin Management System (Insulet Corp.) was used, and the
insulin infusion and the pre-meal bolus were managed by a control algorithm
that was initiated at 5:00 p.m. in a data-collection mode and used from 9:30
p.m. to 12:00 a.m..
In both admissions subjects received dinner (70.7 ± 3.3 g of CHO) between
6:00 p.m. and 7:00 p.m. and breakfast (52.9 ± 0.1 g of CHO) between 7:00
a.m. and 8:00 a.m.. For each subject, meals were the same in the two admis-
sions. A scheme of the protocol design is shown in Figure 3.1. Throughout
the admissions, venous blood samples were collected every 30 min right after
each meal ingestion for measurements of plasma glucose and insulin concen-
trations, or every 15 min if hypoglycemia was occurring or imminent.
Plasma glucose was measured using YSITM 2300 STAT Plus Analyzer (YSI
Inc., Yellow Springs, OH, USA). As it will be discussed in Chapter 4.1, for
the speciﬁc purpose of the thesis to be achieved using this dataset (i.e. the
clinical assessment of the simulator, see Chapter 4), it is not needed to keep
the data of each admission separately, since the results will be not dependent
from the algorithm used in the trial. Thus, average time courses of plasma
glucose and insulin are shown aggregated in Figure 3.2. A detailed descrip-
tion of the clinical protocol is reported in [44].
OPEN-/CLOSED-LOOP 
15:00 21:00 
time 
03:00 06:00 09:00 12:00 18:00 
Admission 1&2 
30’ * Sampling 
00:00 
Breakfast Dinner 
Figure 3.1: Overview of the admission day. Patients underwent open- or closed-
loop and were served dinner and breakfast.
*: sampling time reduced to 15 min if hypoglycemia was occurring or imminent.
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Figure 3.2: Average time courses of plasma glucose (upper panel) and insulin
(lower panel) concentrations measured in T1DM subjects (N = 48). Vertical bars
represent the standard deviation SD.
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3.3 Database 2
Database used to validate the T1DMmodel consists of 47 T1DM subjects
(33 males; age = 42.0 ± 10.1 years, BW = 77.5 ± 13.4 kg) [58], recruited in
six clinical centers (Academic Medical Center Amsterdam, NL (N=7); CHRU
Montpellier, FR (N=8); Medical University of Graz, AT (N=8); Proﬁl Insti-
tute for Metabolic Research GmbH, GER (N=8); University of Cambridge,
UK (N=8); University of Padova, IT (N=8)), within the AP@home FP7-
EU project. Subjects underwent three randomized 23-hour admissions, i.e.
one open- and two closed-loop sessions. During the open-loop admission,
subjects had their usual insulin therapy through an insulin pump, while the
insulin infusions were managed by a control algorithm during the closed-loop
admissions. For each admission, subjects received standard solid meals at
dinner D (7:00 p.m., Day 1), breakfast B (8:00 a.m., Day 2) and lunch L
(12:00 a.m., Day 2), respectively containing 80g, 50g and 60g of CHO, and
did a moderate physical activity session (3:00 p.m., Day 2). A scheme of the
protocol design is shown in Figure 3.3. Throughout the admissions, venous
blood samples were collected for measurements of plasma glucose and insulin
concentrations every 15 min in the ﬁrst 2 hours after each meal, every 1 hour
at night and every 30 min elsewhere.
Plasma glucose was measured using YSITM 2300 STAT Plus Analyzer (YSI
Inc., Yellow Springs, OH, USA) and plasma insulin was measured using an
insulin chemiluminescence assay (Invitron Ltd, Monmouth, UK) (The Insti-
tute of Life Sciences, Swansea University, S. Luzio). A detailed description
of the clinical protocol is reported in [58]. It is worth noting that the analysis
conducted with this dataset to validate the T1DM model (see Chapter 5) is
not dependent from the admissions. Thus, also in this case, average measures
of plasma glucose and insulin are plotted together in Figure 3.4.
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OPEN-/CLOSED-	LOOP	Admission	1-3	
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&me	
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60’	Sampling	
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15’	15’	30’	15’	 30’	 30’	30’	 15’	 30’	
Figure 3.3: Overview of the admission day. Patients underwent open- or closed-
loop and received dinner, breakfast and lunch. A 30-min session of physical exercise
started at 3:00 p.m..
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Figure 3.4: Average time courses of plasma glucose (upper panel) and insulin
(lower panel) concentrations measured in T1DM subjects (N = 141). Vertical bars
represent the standard deviation SD.
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3.4 Database 3
The database employed to develop the model of intra-subject diurnal
variability of insulin sensitivity consists of 20 T1DM subjects (11 males; age
= 42.9 ± 14.4 years; BW = 74.7 ± 15.4 kg; CR = 8.6 ± 2.1 g/U) [34], who
were admitted for a 3-day study in the Clinical Research Unit of the Mayo
Center for Clinical and Translational Science (Rochester, MN).
In brief, once a day, a triple-tracer mixed-meal study protocol [4] was per-
formed during breakfast (B), lunch (L), or dinner (D) in a randomized Latin
square design (see Table 3.1 for an example), with identical meal composition
(50 g of CHO). Blood samples were collected at t = -180, -30, 0, 5, 10, 20,
30, 60, 90, 120, 150, 180, 240, 300, and 360 min, with t = 0 corresponding
to the timing of the meal, for measurement of plasma glucose and insulin
concentrations.
Plasma glucose was measured using YSITM 2300 STAT Plus Analyzer (YSI
Inc., Yellow Springs, OH, USA) and plasma insulin was measured by a two-
site immunoenzymatic assay performed on the DxI automated immunoassay
system (Beckman Coulter Inc., Chaska, MN). A detailed description of the
clinical protocol is reported in [34]. Since this dataset will be used to assess
the intra-subject diurnnal variability of insulin sensitivity (see Chapter 6), it
is important to highlight the possible diﬀerences existing in plasma concen-
trations measured at B, L and D. Thus, in this case, average time courses
of plasma glucose and insulin at B, L and D are shown separately in Figure
3.5.
Table 3.1: Latin Square Randomization
Day 1 Day 2 Day 3
Breakfast 
Lunch 
Dinner 
Randomization order in an illustrative subject:  means that the triple-
tracer approach is used. In this example, the triple-tracer is used at
dinner of Day 1, breakfast of Day 2, and lunch of Day 3.
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Figure 3.5: Average time courses of plasma glucose (upper panel) and insulin
(lower panel) measured at breakfast (B), lunch (L), and dinner (D) in T1DM
subjects (N = 20). Vertical bars represent the standard deviation SD.

4
Clinical Assessment of the T1DM Simulator
4.1 Introduction
As already stated in Chapter 1.1.3, the UVA/Padova T1DM Simulator
has been successfully used by several research groups in academia, as well as
by companies active in the ﬁeld of T1DM. However, its validity was never
been validated against T1DM data obtained in clinical trials. In this chapter,
the clinical assessment of the UVA/Padova T1DM Simulator is presented.
Brieﬂy, both the ﬁrst (S2008) and the last (S2013) versions of the simulator
were assessed against a real T1DM population by undergoing the in silico
adults to the same protocol of the real subjects, i.e. the virtual subjects
received the same meal and insulin delivery of the real ones. The procedures
are described in details in the following sections.
The experimental data used for the clinical assessment of the simulator
are those of Database1 described in Chapter 3.2. In particular, because the
virtual subject receives the same insulin amount used by the real subject,
the results are in principle independent from the algorithm used in the trial,
so that no diﬀerence between study admissions are considered. Moreover,
each glucose trace is subdivided into post-dinner (from dinner ingestion to
7 h later), overnight (from 5 h after dinner to the beginning of breakfast),
and post-breakfast (from breakfast ingestion to 5 h later) portions, so that a
total of 96 post-meal traces are considered.
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4.2 Model assessment
The simulator assessment aims to prove the following statements:
1. For each real T1DM subject, a virtual subject exists who, if undergoing
the same experimental scenario (i.e., same meal CHO amount, insulin
boluses, and basal pattern, given at the same time), behaves similarly
to the real one from a clinical point of view, i.e. it shows a similar
pattern and lies in the same clinically relevant zones, as illustrated in
Figure 4.1. In particular, the clinical relevant zones are the hypo-,
eu-, and hyper-glycemc zones, for which blood glucose levels are < 70
mg/dL, between [70− 180] md/dL, and > 180 mg/dL, respectively.
2. The distribution of the most important clinical outcome metrics in the
simulated traces reproduces those observed experimentally.
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Figure 4.1: Matching criterion: a real T1DM subject, receiving a certain amount
of CHO with a meal and insulin basal infusion and bolus, exhibits a hyperglycemic
glucose peak after meal and a hypoglycemic event during the second half of the
experiment (left side). Among the 100 in silico subjects receiving the same meal
and insulin amounts (right side), the one showing the best agreement in exploring
the clinical zones is selected as best match.
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To test the ﬁrst requirement, each measured plasma glucose proﬁle is
compared with those simulated in the 100 in silico adults, who undergo the
same experimental scenario (meals, basal insulin, and boluses). In particular,
for each pair real-virtual subject an index (FIT), quantifying the agreement
between real and virtual glucose trace, is calculated as:
FIT = 1−
√ ∑N
k=1(G
meas(tk)−Gsim(tk))2∑N
k=1(G
meas(tk)−Gmean(tk))2
(4.1)
where Gmeas is the measured and Gsim is the simulated blood glucose con-
centration, Gmean is the average measured glucose, and N is the number of
samples. Among the 100 simulated proﬁles, the one providing the best FIT
is selected and compared with the real glucose proﬁle by using the Continu-
ous Glucose Error Grid Analysis (CG-EGA) [48]. The CG-EGA method was
originally developed for the clinical evaluation of CGM sensors in terms of
both accurate glucose readings and accurate direction and rate of glucose
ﬂuctuations. In brief, CG-EGA compares the CGM proﬁle with the refer-
ence blood glucose (BG) and provides a point-error grid analysis (P-EGA)
[10], combined with a rate-error grid analysis (R-EGA), and an error matrix
(EM). The P-EGA and the R-EGA plot CGM vs. BG and CGM rate of
change vs. BG rate of change, respectively, on a plane divided into speciﬁc
zones, which accounts for the dangerousness of erroneous readings in rela-
tion to the actual glucose level [48][46]. The EM summarizes the results of
the analysis, reporting the percentage of accurate readings, benign errors,
and erroneous readings of the P-EGA and R-EGA. Here this tool is used to
compare glucose measurements (Gmeas) against the simulations (Gsim). An
example is reported in Figure 4.2.
To test the second requirement, the distributions of the most popular
clinical outcome metrics obtained in real and simulated experiments, are
compared. In particular, glucose means and intrasubject interquartile range
(IQR), Low and High Blood Glucose Indices (LBGI and HBGI, represent-
ing two risk statistics related to the individual glycemic control in the hypo-
and hyper- glycemic range [46],[45]), the percentage of BG < 70 mg/dL (hy-
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poglycemia) and BG > 180 mg/dL (hyperglycemia), the percentage of time
in which BG < 70 mg/dL (hypoglycemia) and BG > 180 mg/dL (hypergly-
cemia), the area between 70 mg/dL and the glucose curve when BG < 70
mg/dL (hypoglycemia), the area between 180 mg/dL and the glucose curve
when BG > 180 mg/dL (hyperglycemia), and the number of hypoglycemic
and hyperglycemic events are evaluated. Two sample comparisons are per-
formed using the paired t test, for normally distributed variables, and the
Wilcoxon signed rank test, for variables not-normally distributed, both with
the signiﬁcance level set at P = 0.05.
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Figure 4.2: PP-EGA and R-EGA in an illustrative case (upper panel): as it can
be observed, P-EGA provides all points residing in A zone except for one, which is
in the low-B zone; R-EGA provides two points in low-E zone, two in low-B, and the
remaining in A zone; the resulting EM is provided in lower panel, where accurate
(in white), benign (light blue), and erroneous points (dark blue) are shown.
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4.3 Results
Figure 4.3 shows the comparison between plasma glucose data measured
in one T1DM subject and simulated proﬁles obtained with the S2013 (left
panel) and S2008 (right panel) in one illustrative case. The S2013 well re-
produces the glucose patterns observed in clinical trials in all clinical zones,
in particular the rapid falls in glucose levels and the hypoglycemic episodes.
The simulated proﬁles obtained with the S2008 reproduce quite well the data
in euglycemia and hyperglycemia but not the hypoglycemic episodes.
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Figure 4.3: Data Vs. simulations in one representative subject: S2013 (left
panel) vs. S2008 (right panel). Hypoglycemic threshold (70 mg/dL) is depicted as
dotted line.
The average results of CG-EGA of the S2013 (Table 4.1, ﬁrst row) are very
good in hypo-, eu-, and hyper-glycemia (percentage in accurate + benign
zones: 86.4% in hypoglycemia, 99.9% in euglycemia and 99.2% in hypergly-
cemia). The results of the S2008 (Table 4.1, second row) show that the per-
formance is similar to that of S2013 in eu- and hyper-glycemia (percentage
in accurate + benign zones: 99.8% in euglycemia and 99.5% in hypergly-
cemia) but worse in hypoglycemia (percentage in accurate + benign zones:
40.7%). The improvement presented above is conﬁrmed by the analysis of
the distribution of outcome metrics, reported in Table 4.2. The outcome
metrics of S2013 simulations (Table 4.2, second column) are not statistically
diﬀerent from those obtained from the data, except for the percentage of
time in hypoglycemia and the area under the BG curve for hypoglycemia.
For the S2008 (Table 4.2, third column), most of the outcome metrics are
signiﬁcantly lower in simulation (P < 0.05).
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4.3.1 Comments to results
The results presented above proves the validity of the S2013 model in
terms of ability to reproduce the glucose variability observed during a clin-
ical trial. However, there are some aspects that have to be taken into account.
First of all, the proposed method ﬁnds the in silico subject that best matches
(from a clinical point of view) the observed glucose trace, without any concern
about the similarity of physiological parameters, such as the body weight or
the CR. In these regards, the percent diﬀerence between subject and virtual
parameters was 18% on average for body weight and 67% for CR. The higher
diﬀerence found for CR is due to the fact that the virtual CR (CRsim) is the
optimal one for a given subject. Thus, when doing the comparison, one
should take into account the postprandial glycemic control obtained in the
experiment: for instance, if CRsim is higher than the real one (CRreal), but
(CRreal) makes the subject experience hypoglycemia, one should have ad-
ministered less insulin (i.e., applying a higher CR for that meal); conversely,
if the CRsim is lower than the real one, but the (CRreal) makes the subject
experience hyperglycemia, one should have administered more insulin (i.e.,
applying a lower CR for that meal). This analysis revealed that a diﬀer-
ence between real and virtual CR grater than 50% was found in 23 subjects.
However, 14 of them would have beneﬁtted by using a CR closer to the vir-
tual one, potentially avoiding hypo- or hyper-glycemia (an illustrative case
is shown in Figure 4.4).
data 
S2013_CRreal 
S2013_CRsim 
Figure 4.4: Glucose response using CRreal (red) vs. CRsim (green) in one illus-
trative case. By applying the real insulin amount, i.e. using CRreal (= 7 g/U), the
subject experiences hypoglycemia. Conversely, the subject would have beneﬁtted
by using CRsim (= 15 g/U), avoiding hypoglycemia.
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The matching criterion was also applied limiting the search to the in silico
subjects with CR similar to the real one. In this case a match was always
found except for eight traces, which, however, presented hypoglycemia, and
thus the corresponding CR were too agressive, as explained above. This pro-
cedure also provided similar results in terms of CE-EGA.
Moreover, the assessment was done by assuming no relation between the post-
prandial portion of the same subject (i.e. post-dinner and post-breakfast, in
both study admissions). Indeed, a single in silico subject was unable to
simultaneously match post-prandial glucose proﬁle at dinner and breakfast.
This was in some sense expected, because the model of the simulator was,
at the time of the development of this method, not able to describe glucose
variability in a multiple-meal scenario. This outcome suggests that diﬀer-
ent meal composition results in diﬀerent glucose traces and/or time varying
parameters (e.g. insulin sensitivity) should be included in the simulator to
better ﬁt the physiology. These are speciﬁcally the aims of the following two
chapters.
The method to assess the simulator against T1DM data, as well as the
obtained results, have been published in [95].

5
Validation of the T1DM model
5.1 Introduction
The clinical assessment of the simulator, presented in Chapter 4, showed
that, for each T1DM patient of Database1, an in silico subject exists who
clinically matches the real data, thus proving that the virtual subjects are
representative of a T1DM population observed in a clinical trial. This was
an important feature of the simulator to be used in preclinical trials. How-
ever, this does not demonstrate the goodness of the model nor the adequacy
of the joint parameter distribution included into the simulator. In addition,
the fact that two diﬀerent in silico subjects were required to well match the
post-dinner and post-breakfast glucose traces of the same real subject means
that a good simulation model should at least take into account that diﬀerent
meal compositions may product diﬀerent glucose proﬁles. Moreover, account-
ing for circadian variability of important parameters, like insulin sensitivity
(SI), i.e. a parameter that quantiﬁes the eﬀect of insulin to stimulate the
whole-body (liver and periphery) glucose disposal and inhibit the glucose
production, may be needed.
In this chapter, the simulator model is validated by ﬁtting it, for the
ﬁrst time, against data of a large number of T1DM subjects, who underwent
three 23-hour admissions and received breakfast, lunch and dinner containing
diﬀerent amounts of CHO (Database2, Chapter 3.3). However, the available
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data consists of only plasma glucose and insulin measurements and meal
CHO contents. This precludes the possibility to identify the model with
the approach described in Chapter 2.2.2: in fact, given the lack of glucose
ﬂuxes, i.e. meal glucose rate of appearance (Rameal), endogenous glucose
production (EGP ), glucose utilization (U), renal excretion (E), it is not
possible to univocally identify all the single processes of the model with
weighted least squares or maximum likelihood identiﬁcation techniques. On
the other hand, Bayesian parameter estimation techniques can be used in
such conditions, since they exploit a certain a priori statistical knowledge to
supply the lack of data. As a matter of fact, in the following a Bayesian
method to identify the S2013 model is presented. The natural choice was to
exploit the parameter joint distribution employed for the generation of the
in silico subjects of the simulator and use it as a priori knowledge.
5.2 The Bayesian estimator Maximum a Pos-
teriori
Given the complexity of the model, the sole availability of plasma glu-
cose and insulin data makes it impossible to reliably identify the model by
using a weighted least squares or maximum likelihood estimator. In fact, one
can obtain a good description of plasma glucose and insulin data with many
diﬀerent descriptions of the metabolic ﬂuxes (i.e. Rameal, EGP , U and E);
in other words, a good model ﬁt can be achieved with several combinations
of model parameters. To overcome this problem, a Bayesian approach is
adopted, i.e. the estimation of the model parameter vector p takes account
of both the information provided by the data vector z, i.e. the a posteriori
information, and the knowledge on the a priori joint distribution of p, as-
sumed independent form z. In particular, the Maximum a Posteriori (MAP)
Bayesian estimator provides a point estimate p so that, once ﬁxed z, the a
posteriori probability density of p is maximum:
pˆMAP = argmax
p
f(p|z)(p|z) (5.1)
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where
f(p|z)(p|z) =
f(z|p)(z|p)fp(p)
fz(z)
(5.2)
with fp(p) denoting the a priori probability density of p, considered random,
fz(z) the a priori probability density of z, and f(z|p)(z|p) the a posteriori
probability density of z. Assuming that z is aﬀected by measurement error
v, Gaussian, with zero mean and covariance Σv, and p is extracted from a
Gaussian distribution with mean µp and covariance Σp, equation (5.1) can
be rewritten as:
pˆMAP = argmin
p
{
[z −G(p)]TΣ−1v [z −G(p)] + [p− µp]TΣ−1p [p− µp]
}
(5.3)
with G(p) denoting the model prediction. In other words, the ﬁrst term in
equation (5.3) represents the model ﬁt, while the second term is the distance
of the estimated parameters from their joint distribution. To guarantee the
non-negativity of model parameter estimates, here the parameter distribution
is assumed to be lognormal:
s = log (p) (5.4)
Therefore, the estimated parameter vector can be expressed as
pˆ = exp (sˆ) (5.5)
where
sˆ = argmin
s
{
[z −G(exp(s))]TΣ−1v [z −G(exp(s))] + [s− µs]TΣ−1s [s− µs]
}
(5.6)
with µs and Σs denoting the mean and the covariance matrix in logaritmic
form. More details on MAP estimation can be found in [12].
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5.3 Model identiﬁcation
The T1DM simulator does not yet account for the eﬀect of physical activ-
ity on glucose dynamics. Thus, the model identiﬁcation is performed using
data of Database2 [58] excluding physical exercise portions, which however
occurred at the end of the experiment. Hence, the model is identiﬁed on
20-hour plasma glucose data using the MAP estimator. In order to avoid
local minima, the minimization of the objective function is performed using
a cascade of a direct search method followed by a gradient-based algorithm.
Measurement error is assumed to be additive, Gaussian, with zero mean and
constant coeﬃcient of variation (CV) of 2%. Plasma insulin concentration
is the model forcing function and is assumed to be known without error.
Moreover, being glucagon measurements not available, the average glucagon
model parameters are used. Interestingly, model identiﬁcation provides, in
addition to model parameters, an estimation of the main glucose ﬂuxes, i.e.
Rameal (equation (2.10)), EGP (equation (2.27)), U (equations (2.12),(2.29))
and E (equation (2.15)). However, when presenting the results, the net rate
of disappearance Rdnet (deﬁned as Rdnet = U + E − EGP ) is shown since
without glucose tracers, even with a strong prior, it could be diﬃcult to sep-
arately estimate U , E and EGP contributes.
The a priori information in equation (5.6) is the joint parameter distribution
used to generate the in silico adult population included into the T1DM simu-
lator. To describe post-prandial glucose pattern at diﬀerent times of the day,
variability of parameters describing glucose absorption (i.e. kabs, kmax, kmin
in equations (2.10),(2.11)) is permitted, under the assumption that diﬀerent
meal composition at breakfast B, lunch L, and dinner D results in diﬀer-
ent absorption parameters. The other parameters are maintained constant
throughout the day. However, with this setting, model ﬁt to the data was
not satisfactory (not shown). Therefore, variation in parameters describing
SI (i.e. kp3 and Vmx in equations (2.27),(2.29)) is permitted. In particular,
kp3 and Vmx are allowed to be diﬀerent at B with respect to L and D, while
L and D are set to be equal. These assumptions are based on the ﬁndings of
a recent study [34], in which T1DM subjects exhibited a SI trend lower at
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B compared to L and D. It is worth noting that, at variance with [34], here
SI parameters at L and D are assumed to be the same in each subject, due
to the small amount of samples collected between lunch and physical exer-
cise. This was necessary to guarantee that kp3 and Vmx at L are estimated
with good precision. As a matter of fact, this dataset was not adequate to
test intra-day variability of SI parameters, due to both the short duration of
the post-lunch data portion and the possible confounding eﬀect introduced
by diﬀerent compositions and CHO contents of the meal (the assessment of
daily variation of insulin sensitivity is tackeled in Chapter 6). The intra-
day variability is implemented for each time-varying parameter as an almost
step-wise-line signal that varies three times a day.
5.4 Results
5.4.1 Fit, Parameters and Fluxes
The model is identiﬁed in all the available 141 glucose traces, and well
ﬁts the glucose data, as proved by the average weighted residuals time course,
shown in Figure 5.1. An example of the glucose model ﬁt in a representative
subject is shown in Figure 5.2, upper panel. In addition, the model-derived
time courses of Rameal and net rate of disappearance Rdnet are provided (Fig-
ure 5.2 middle and bottom panels).
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Figure 5.1: Average weighted residuals (vertical bars represent standard devi-
ation (SD)) of model ﬁt on plasma glucose data (N = 141).
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Figure 5.2: Model prediction vs. plasma glucose concentration (upper panel)
and the corresponding glucose ﬂuxes, i.e. Rameal (middle panel) and Rdnet (lower
panel), provided by the model in an illustrative subject. Data are indicated with
dots, while model predicted plasma glucose and ﬂuxes are shown with continuous
lines. B, L, D, HT indicate breakfast (50 CHO grams), lunch (60 CHO grams),
dinner (80 CHO grams) and hypoglycemia treatment (10 CHO grams), respectively.
In order to assess the goodness of the model ﬁt, the coeﬃcient of determ-
ination (R2) and the index FIT (already deﬁned in Chapter 4.2) have been
calculated. In this regard, mean ± SD (min−max) of R2 and FIT are
0.962± 0.027(0.854− 0.996) and 0.812± 0.066(0.615− 0.934), respectively.
The precision of parameter is evaluated based on the coeﬃcient of variation
(CV, deﬁned as the ratio between the standard deviation of the estimated
parameter and the parameter value), which is related to how much a vari-
ation of a speciﬁc parameter inﬂuences the model prediction (the lower the
CV, the higher the sensitivity of model prediction to the parameter). As
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expected, having resorted to a Bayesian approach, model parameters are es-
timated with good precision (CV = 1.3%± 0.2%), despite the complexity of
the model with respect to the available data.
5.4.2 Intra- and Inter-Subject Variability
The a posteriori distribution of model parameters is generally in agree-
ment with that included in the UVA/Padova simulator. However, some dif-
ferences occur. In particular, glucose gastric emptying parameters at B are
signiﬁcantly diﬀerent from those at L and D (Figure 5.3), reﬂecting a more
rapid glucose dynamics at B, likely due to the diﬀerent meal compositions of
the B vs. L and D. On the other hand, insulin sensitivity varies during the
day in a subject-speciﬁc fashion, without showing a consistent pattern in the
population (Figure 5.4), in agreement with what already reported in [34].
The complete lists of glucose absorption and insulin sensitivity parameter
estimates are reported in Table 5.1 and Table 5.2 (page 52). The comparison
among parameter distributions included in the simulator and those obtained
at B, L, and D in this study are shown in Figure 5.5 and 5.6, for the glucose
absorption (i.e. kabs, kmax, kmin) and the insulin sensitivity parameters (Vmx,
kp3), respectively. In particular, concerning the absorption parameters (Fig-
ure 5.5), the mean for L and D are signiﬁcantly lower than those of B and
the simulator (P < 0.0001 when comparing L and D against both B and the
simulator prior), except for kabs, which does not exhibit signiﬁcant diﬀerences
among B, L and D. On the other hand, distributions of insulin sensitivity
parameters at B, L, D, and the simulator (Figure 5.6) are not statistically
diﬀerent (P > 0.05 from Wilkoxon Signed Rank Test when comparing L&D
against both B and the simulator prior).
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Figure 5.3: Glucose absorption parameters kabs, kmax and kmin estimated at
breakfast B (red), lunch L (green), and dinner D (blue). Vertical bars represent
standard error (SE). *P < 0.05 with respect to B, from Wilcoxon Signed Rank
Test.
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Figure 5.4: Insulin sensitivity parameters Vmx and kp3 estimated at breakfast B
(red) and lunch&dinner L&D (green). Vertical bars represent standard error (SE).
*P < 0.05 with respect to B, from Wilcoxon Signed Rank Test.
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Figure 5.5: Distribution of glucose absorption parameters kabs, kmax and kmin
at breakfast B (red), lunch L (green), and dinner D (blue) compared to the prior
(grey area).
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Figure 5.6: Distribution of insulin sensitivity parameters Vmx and kp3 at break-
fast B (red) and lunch&dinner L&D (green) compared to the prior (grey area).
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Table 5.1: Glucose Absorption Parameters
Parameter B L D
kabs 0.130 [0.092-0.174] 0.130 [0.076-0.216] 0.147 [0.098-0.209]
(min−1) (NS) (NS)
kmax 0.040 [0.027-0.059] 0.028 [0.021-0.041] 0.030 [0.021-0.043]
(min−1) (<0.0001) (<0.0001)
kmin 0.015 [0.009-0.019] 0.010 [0.005-0.015] 0.008 [0.005-0.011]
(min−1) (<0.0001) (<0.0001)
Values are reported as median [IQR] (P value with respect to B, from Wilcoxon Signed
Rank Test). NS, not signiﬁcant (P > 0.05).
Table 5.2: Insulin Sensitivity Parameters
Parameter B L&D
Vmx 0.051 [0.034-0.090] 0.058 [0.037-0.080]
(mg/kg/min per pmol/l) (NS)
kp3 0.015 [0.006-0.025] 0.014 [0.008-0.033]
(mg/kg/min per pmol/l) (NS)
Values are reported as median [IQR] (P value with respect to B, from Wilcoxon Signed
Rank Test). NS, not signiﬁcant (P > 0.05).
5.4.3 Assessment of a Priori Parameter Distribution
The Bayesian MAP estimation technique is a very powerful tool to identify
models whenever the available data are scarce in comparison to model com-
plexity. However, the choice of the prior distribution is critical and inﬂuences
the ﬁnal parameter estimates. If the prior is too informative (small variance),
the risk is that parameter estimates collapse into the prior and the model does
not ﬁt the data well. On the other hand, if the prior is not informative enough
(large variance), the parameter estimates may be imprecise. Ideally, the a
priori information and the a posteriori information should be well balanced.
This is reasonably achieved if the ﬁt of the data is good and the parameter
estimates are precise. However, this performance does not guarantee that
the a priori parameter distribution is representative of our type 1 diabetic
population. To investigate the agreement between prior and posterior and
the stability of the solution, the parameter distributions are compared using
the Wilkoxon Signed Rank test and the iterative two-stage method. For sake
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of convenience, let's call Stage1 the model identiﬁcation performed using the
prior included into the simulator, Stage2 the model identiﬁcation performed
using the posterior obtained from Stage1 as new prior, and so on. The pos-
teriors are thus compared with the priors after each iteration, i.e. Stage2 vs.
Stage1, Stage3 vs. Stage2, etc. In particular, for each subject, the absolute
relative diﬀerence δpj is calculated as:
δpj = [δp1,j, . . . , δpn,j], j ≥ 2 (5.7)
with
δpi,j =
∣∣∣∣pi,j − pi,j−1pi,j−1
∣∣∣∣, i ∈ [1, . . . , n] (5.8)
where pi,j is the value of i -th parameter estimated at the j -th stage, and
n is the number of model parameters. The lower the δpi,j the better the
agreement between prior and posterior.
After the ﬁrst iteration, the posteriors obtained at Stage1 and Stage2 are
not statistically diﬀerent except for kabs at breakfast (P = 0.03). As concerns
the absolute relative diﬀerence, mean ± SD of δp2 is 0.059± 0.044, mean ±
SD of δp3 is 0.045± 0.035 and mean ± SD of δp4 is 0.034± 0.028.
5.4.4 Comments to results
The obtained results prove that the Bayesian approach is able to cope
with the identiﬁcation of the T1DM model: in fact, despite the large number
of parameters, by using the a priori information included into the UVA/Padova
simulator, it is possible to well predict the glucose time courses of 141 ex-
periments in T1DM subjects. Model parameters are estimated with good
precision and their posterior distribution is in agreement with that included
in the simulator. By using an iterative two-stage approach it has been demon-
strated that the relative diﬀerences in model parameters are modest, getting
smaller and smaller at each iteration, lower than 5% already after the second
iteration. Similarly, the posterior distributions are statistically identical ex-
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cept for some of the absorption parameters. This result was in some sense
expected, since these parameters have to vary more than the others, since the
meal composition in the Database2 (solid meal) is diﬀerent from that used
for generating the prior of the simulator (Jell-O meal, see Chapter 2.2.2, [3]).
Taken together, these results conﬁrm that the model included into the sim-
ulator is adequate to describe T1DM glucose dynamics, and that the choice
of the prior is key. Here the choice has been to exploit the parameter distri-
bution included into the simulator, which was derived from multiple tracer
data [3, 22]. In principle, other distributions can be used, and it is likely that
diﬀerent a priori parameter distributions would lead to diﬀerent parameter
estimates, and thus to diﬀerent a posteriori distributions. In this regard, the
prior included into the simulator is meant adequate, since it provides repeat-
able parameter solutions: in fact, the distribution of constant parameters
remains the same among the subsequent iterations, and, at the same time,
the ﬁtting procedure is sensitive enough to capture the variation of the im-
portant parameters, e.g. those related to the meal composition and insulin
sensitivity.
Concerning the intra- and inter-subject variability, it is important to point
out that the signiﬁcant diﬀerences observed in distributions of glucose ab-
sorption parameter (Figure 5.5) were expected: in fact, the parameter distri-
butions of the simulator were obtained from subjects who received a mixed
meal containing rapidly absorbed carbohydrates. Hence, it is reasonable that
the posterior distribution estimated at B is virtually superimposable to the
prior, since, usually breakfast contains fast absorbing CHO, while the pos-
terior distributions estimated at L and D are statistically diﬀerent from the
original ones, since usually those meals are characterized by a slower absorp-
tion. This, again, supports the notion that the information content in the
data is rich enough to observe this important variation in model parameters
and that the prior is not too constraining, so that model parameters are al-
lowed to move away from it, if data say so.
On the other hand, results found in insulin sensitivity (Figure 5.6) conﬁrm
what already reported in Hinshaw et al. [34], even if, as already anticipated
in paraghraph 5.3, this dataset is not fully adequate to draw strong conclu-
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sions in this regard.
These results prove the validity of the model and the prior included into
the T1DM simulator, provided that variations of some key parameters are
allowed during the day, as already dicussed in other similar works, e.g. [32].
Further analysis will have to be done in order to include in the simulator
a robust model of glucose absorption depending on meal composition, e.g
exploiting data of a recent experiment on complex carbohydrate metabolism
[79]. Conversely, a model of daily variation of insulin sensitivity is proposed
in the following Chapter 6.
The proposed Bayesian method has proved to be a valid approach to identify
the T1DM simulation model, so that it could be applied to exploit the huge
amount of data available from the clinical trials, and thus it could allow
understanding how the model parameters change in response to speciﬁc ex-
perimental conditions. In this regard, further developments are required in
order to make the method usable with CGM sensor and insulin pump data,
such as including the insulin kinetic subsystem and using some appropriate
signal preprocessing, e.g. retrospective ﬁtting [26], able to reliably estimate
the original blood glucose from CGM sensor measurement.
The Bayesian approach and the results presented above have been in-
cluded in a manuscript, currently under revision [94].

6
Model of the intra-day variability of insulin
sensitivity
6.1 Introduction
As anticipated in Chapter 4, the time-invariant characteristic of the
UVA/Padova T1DM simulator limits its validity to a single meal scenario.
In Chapter 5, it was found that the variability of meal CHO content, and
thus the variability of the meal rate of appearance, is not suﬃcient to com-
pletely explain diﬀerent glucose pattern at breakfast, lunch and dinner, and
variations in insulin sensitivity (SI) parameters are also needed.
In this chapter, a model of intra-day SI variability is developed and in-
corporated in the simulator. To do that, data of [34] are employed, i.e.
Database3 described in Chapter 3.4, consisting of 20 T1DM subjects studied
in three separated occasions, respectively at breakfast (B), lunch (L) and
dinner (D). In particular, in [34] SI was estimated from plasma glucose and
insulin concentrations at B, L and D with the oral minimal model [13]. The
protocol was suitable for that purpose, since identical meals were admin-
istered at B, L and D, thus avoiding confounding eﬀects of CHO content and
meal composition on SI estimation. As reported in that work, the results
proved the existence of diurnal patterns of SI, with SI lower at B than L and
D, on average (Figure 6.1a). However, this diﬀerence was not statistically
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signiﬁcant, due to both the small population size and the high inter-subject
variability (Figure 6.1b).
The idea is thus to use these data to analyze the possible pattern of SI intra-
day variability for each subject, to assess the occurrence of each pattern in
the population, and to incorporate this information into the simulator. This
procedure allows extending the domain of validity of the simulator, making
it suitable to perform longer realistic in silico trials.
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Figure 6.1: (a) Average insulin sensitivity at diﬀerent time of the day (breakfast
[B], lunch [L], and dinner [D]). Data are mean ± SE values. (b) Percentage intra-
day insulin sensitivity variation at B, L, and D.
6.2 Classiﬁcation of insulin sensitivity pattern
To highlight the characteristic SI pattern in each subject, each SI value
is ﬁrst normalized to the maximum observed in the same subject:
SIj =
SIj
max([SIB, SIL, SID])
j = [B,L,D] (6.1)
Then, a threshold is chosen, for which values above threshold are labeled as
high (h), whereas values below threshold are labeled as low (l). The threshold
value is determined on the basis of the precision of the SI estimates: more
6.2 Classiﬁcation of insulin sensitivity pattern 59
precisely, in [34] SI was estimated with a precision of 20%, on average; assum-
ing SI maximum at B (i.e. 100%), the SI values at L and D are considered
to be diﬀerent from that at B if they are outside the two-sigma (i.e. 95%)
conﬁdence interval (i.e. below 100% − 2 × 20% = 60%). By this consider-
ation, the threshold is ﬁxed to 60%, therefore a 40% diﬀerence is assumed
to be imputable to a fortuitous variation and is subsequently modeled as a
random eﬀect.
With this deﬁnition, there are seven possible empirical classes, each one as-
sociated with a particular diurnal pattern of SI at B, L, and D (Figure 6.2a):
• Class 1: h-h-h (equivalent to l-l-l)
• Class 2: h-h-l
• Class 3: h-l-h
• Class 4: h-l-l
• Class 5: l-h-h
• Class 6: l-h-l
• Class 7: l-l-h
Each subject is univocally associated with one of the above classes. The
probability of each class is then calculated as:
P (Class i) = Ni/Ntot (6.2)
where Ni is the number of subjects belonging to the i -th Class and Ntot is
the total number of subjects.
The classiﬁcation results are shown in Figure 6.2b, in particular:
• Two subjects into Class 1 → P (Class 1) = 0.1
• One subject into Class 2 → P (Class 2) = 0.05
• One subject into Class 3 → P (Class 3) = 0.05
• Two subjects into Class 4 → P (Class 4) = 0.1
• Four subjects into Class 5 → P (Class 5) = 0.2
• Four subjects into Class 6 → P (Class 6) = 0.2
• Six subjects into Class 7 → P (Class 7) = 0.3
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(a) (b) 
Figure 6.2: (a) The seven possible classes of insulin sensitivity diurnal pattern.
B, breakfast; L, lunch; D, dinner. (b) Percentage intra-day insulin sensitivity
variation at breakfast (B), lunch (L), and dinner (D), clustered among the seven
variability classes. Percent values reported on the top of each panel represent the
percentage of the population belonging to the respective variability class.
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6.3 Incorporation of the intra-day variability of
insulin sensitivity into the T1DM simulator
In order to implement the intra-day variability of SI into the T1DM sim-
ulator, each in silico subject is randomly assigned to one of the previously
deﬁned seven classes, according to the estimated probability (Figure 6.2b).
The fact that a subject belongs to the i -th Class means that the SI daily pat-
tern of that subject, described by parameters kp3 and Vmx (model equations
2.27, 2.29), is on average the one associated to the i -th Class. For instance,
if the j -th subject, characterized by insulin sensitivity (kjp3, V
j
mx), belongs to
Class 5 (l-h-h), its parameters will be, on average, (αkjp3, αV
j
mx), (k
j
p3, V
j
mx),
and (kjp3, V
j
mx), respectively, at B, L, and D, with α < 1.
Parameter α is set to 0.4, based on the fact that, in each class, low SI
values are (mean ± SD) 40%± 23% of the high. However, deviations from
the nominal proﬁle are allowed, by modulating the nominal pattern with a
multiplicative random noise v, described by a normal distribution N (µ, σ2),
with µ = 1 and σ = 0.2. Parameter σ is chosen in order to explain a random
eﬀect deviation up to 40% of the maximum. The actual Vmx and kp3 patterns
are then transformed in the corresponding time-varying parameters Vmx(t)
and kp3(t) (i.e., an almost stepwise-line signal that varies three times a day).
For example, for the j -th subject belonging to Class 5 the step-wise Vˆmx(t)
signal at the i -th day is deﬁned as:
Vˆmx(t) = V
j
mx ·

vD,i−1 if t < tB,i
α · vB,i if tB,i ≤ t < tL,i
vL,i if tL,i ≤ t < tD,i
vD,i if t ≥ tD,i
(6.3)
where tB,i, tL,i, tD,i deonte the transition times at which VˆmxD,i−1 → VˆmxB,i,
VˆmxB,i → VˆmxL,i, VˆmxL,i → VˆmxD,i, while vD,i−1, vB,i, vL,i, vD,i are the random
noise values related to VˆmxD,i−1, VˆmxB,i, VˆmxL,i, VˆmxD,i, respectively (Figure
6.3, dashed orange line). Then, Vmx(t) is obtained from Vˆmx(t), by smoothing
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the step variation. For example, the transition VˆmxB,i → VˆmxL,i at the i -th
day is deﬁned as:
Vmx(t) = VˆL,i +
VˆB,i − VˆL,i
2
· − tanh[β · (t− c ·∆t] + 1
0.5 · {− tanh[β · (−c ·∆t)] + 1} tB,i ≤ t < tL,i
(6.4)
where ∆t = tL,i − tB,i, c is ﬁxed to 0.2, and β = 5/(2 · c · ∆t) (Figure 6.3,
continuous red line). The same procedure is followed to obtain kp3(t). Figure
6.3 shows the procedure described above for parameter Vmx in an illustrative
subject of Class 5.
0.10 
(m
g
/k
g
/m
in
 p
e
r 
p
m
o
l/
L
) 
0.08 
0.06 
0.04 
0.02 
0 
Dinner Breakfast Lunch Dinner 
Intra-Day Insulin Sensitivity 
00:00 00:00 03:00 06:00 09:00 12:00 18:00 21:00 15:00 
Nominal Vmx Class 5 
Vmx(t) 
Vmx(t) 
^ 
Time (h) 
Figure 6.3: Intra-day insulin sensitivity parameter (Vmx) proﬁle for a virtual
subject belonging to Class 5: Vmx nominal pattern is depicted as pointed blue line,
of which the 100% is the original time-invariant value (here set at 0.08 mg/kg/min
per pmol/L); step-wise Vˆmx(t) is reported as continuous red line; Vmx(t) is depicted
as continuous red line.
6.3.1 In silico subjects update: time-varying carbohydrate-
to-insulin ratio
After the incorporation of the time-varying insulin sensitivity into the
T1DM simulator, three CR values (for B, L and D, respectively) have been
calculated for each in silico subject, using the procedure explained in Chapter
2.3.3. In particular, each subject received 50 g of CHO in two occasions, i.e.
with Vmx and kp3 parameters set to, respectively, 100% or 40% of their origin-
ally constant values; then, CR has been determined for both the occasions
(respectively CR100 and CR40), through the same procedure explained in
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Chapter 2.3.3; ﬁnally, the sequence of three CR values has been properly
obtained by combining CR100 and CR40 according to the average nominal
SI daily pattern (e.g. for subjects belonging to Class 5 the CR sequence is
CR40, CR100, and CR100, at B, L, and D, respectively). Consequently, also
the total daily insulin (TDI) and the correction factor (CF) have been re-
calculated (similarly to what explained in Chapter 2.3.3). Distributions of
Vmx, kp3 and CR at B, L, and D are shown in Figure 6.4: as it can be noted,
VmxB is, on average, lower than VmxL and VmxD (similarly, kp3B is, on aver-
age, lower than Vp3L and Vp3D); consisently, CR values are lower, i.e. more
aggressive, at B compared to L and D.
0 0.1 0.2
0
20
40
(mg/kg/min per pmol/L)
V
mxB
0 0.02 0.04
0
20
40
(mg/kg/min per pmol/L)
kp3B
0 20 40
0
10
20
30
(g/U)
CRB
0 0.1 0.2
0
20
40
(mg/kg/min per pmol/L)
V
mxL
0 0.02 0.04
0
20
40
(mg/kg/min per pmol/L)
kp3L
0 20 40
0
10
20
30
(g/U)
CRL
0 0.1 0.2
0
20
40
(mg/kg/min per pmol/L)
V
mxD
0 0.02 0.04
0
20
40
(mg/kg/min per pmol/L)
kp3D
0 20 40
0
10
20
30
(g/U)
CRD
Figure 6.4: Distributions of Vmx (upper), kp3 (middle) and CR (lower panels)
at breakfast (B), lunch (L), and dinner (D).
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6.4 In silico experiments
In order to assess the intra-day variability model included into the simu-
lator, the ability to reproduce in silico the glucose variability observed in the
data is tested. Therefore the experimental scenario of Database3 (described
in Chapter 3.4) is reproduced in silico. More speciﬁcally, the 100 in silico
subjects received B at 7:00 a.m., L at 1:00 p.m., and D at 7:00 p.m., with the
appropriate amount of ingested carbohydrates (50 g of CHO). The optimal
basal insulin is infused in each virtual subject. In contrast, the pre-meal in-
sulin bolus is reduced, on average, by 2U with respect to the one calculated
with the patient optimal CR. In fact, by deﬁnition, with the optimal CR,
plasma glucose would have returned to its target level within the 3 hours,
whereas the data show that the plasma glucose level was still considerably
above target at t = 360 min (see Figure 3.5). It is worth noting that, with
this reduction, the average amount of insulin administered with the bolus is
similar in the real and virtual populations (3.93± 0.22 U vs. 3.54± 0.16 U,
respectively). Transition times related to time-varying Vmx(t) and kp3(t) are
set at 4:00 a.m., 11:00 a.m., and 5:00 p.m. The simulations are thus com-
pared against clinical data. Two-way analysis of variance, including both the
main eﬀects and a term for interaction, is used to assess diﬀerence between
type of data (real vs. simulated) at B, L, and D. In particular, we looked at
the signiﬁcance of the interaction term, which indicates whether or not the
diﬀerences among B, L, and D are aﬀected by the factor type of data. A P
value of < 0.05 is considered signiﬁcant.
6.5 Results
Inter-subject glucose variability is provided in Figure 6.5 against the
glucose time courses observed in the clinical experiment, proving that the
simulator well captures the variability of the data measured after each meal.
Figure 6.6 shows the comparison of simulated (left panel) vs. above-basal
plasma glucose (right panel) curves at B, L, and D. Simulated plasma glucose
values are, on average, slightly lower and with the peaks occurring somewhat
later than the data.
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Figure 6.5: Simulator inter-subject variability (gray area) is compared with
clinical observations (colored lines with dots) at breakfast (upper panel), lunch
(middle panel), and dinner (lower panel).
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Figure 6.6: Over-basal plasma glucose proﬁles obtained in simulation (left panel)
and observed experimentally (right panel). B, breakfast; L, lunch; D, dinner.
Values of area under the over-basal glucose curves are 2.60 ± 0.91 (B),
1.38± 0.91 (L), and 1.44± 1.07 (D) 104 mg/dL·min in silico vs. 2.87± 1.65
(B), 1.98± 1.56 (L), and 2.16± 2.00 (D) 104 mg/dL·min in vivo. Over-basal
peak values are 109±33 (B), 800±29 (L), and 81±30 (D) mg/dL in silico vs.
136± 39 (B), 126± 37 (L), and 125± 48 (D) mg/dL in vivo. The peak times
are 125± 51 (B), 96± 46 (L), and 94± 44 (D) min in silico vs. 81± 24 (B),
74±21 (L), and 68±24 (D) min in vivo. The interaction term from the two-
way analysis of variance is not statistically signiﬁcant in all the comparisons.
Values of area under the over-basal insulin curves are 1.33± 0.47 (B), 1.26±
0.46 (L), and 1.25 ± 0.46 (D) 104 pmol/L·min in silico vs. 1.42 ± 0.98 (B),
0.86 ± 0.67 (L), and 1.10 ± 1.00 (D) 104 pmol/L·min in vivo. Over-basal
peak values are 94 ± 28 (B), 93 ± 38 (L), and 93 ± 39 (D) pmol/L in silico
vs. 116 ± 59 (B), 102 ± 86 (L), and 98 ± 57 (D) pmol/L in vivo. The peak
times are 46± 9 (B), 45± 7 (L), and 45± 7 (D) min in silico vs. 60± 44 (B),
61±36 (L), and 49±37 (D) min in vivo. The interaction term from the two-
way analysis of variance is not statistically signiﬁcant in all the comparisons
except for the peak times (P = 0.036).
6.5.1 Comments to results
By replicating in silico the same experimental protocol of Database3 [34],
it has been demonstrated that the simulated above-basal plasma glucose
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levels are higher at B with respect to L and D, similarly to what observed
in the data. This proves the capability of the simulator, enriched with the
time-varying SI parameters (kp3, Vmx), to better cope with the diurnal glu-
cose variability.
However, it is worth noting that, on average, the simulated post-prandial
excursions are slightly lower, with glucose peaks occurring later than those
observed in the study (Figure 6.6). This can be justiﬁed by the fact that
the T1DM subjects sof Database3 present, on average, a lower CR with re-
spect to the in silico population (CRreal = 8.6 ± 2.1 [range, 6 − 13] g/U vs.
CRsim = 15.9± 5.3 [range, 7− 30] g/U), hence being less sensitive to insulin.
This may explain the existing diﬀerences in glucose dynamics.
Nevertheless, it is also important to note that the inter-subject glucose vari-
ability observed in clinical data is well captured in simulation at B, L and D
(Figure 6.5).
Some considerations have to be taken regarding the transition times and the
modulation of the nominal pattern into the variability model. Clearly, the
choice of the transition times at which nominal kp3 and Vmx vary is arbitrary;
however, the idea is to set them in order to have a stable values of both kp3(t)
and Vmx(t) around each meal. Moreover, modulation with the multiplicative
random noise would allow a subject to temporarily migrate to another vari-
ability class. However, the random noise amplitude of choice permits only
migrations to contiguous classes: for example, a subject belonging to Class
3 can temporarily migrate to Class 1, 4, or 5 but not to Class 2.
As reported before, the cutoﬀ value of 60% derives from the precision of SI
estimated in [34]. However, diﬀerent cutoﬀ values have been tested: 50%
and 70%. With a 50% cutoﬀ, P (Class 2) = 0, whereas using a 70% cutoﬀ,
P (Class 4) = 0. On the other hand, all the classes had nonzero probabilities
using the 60% cutoﬀ. In some sense, the small sample size has conditioned
the choice of the cutoﬀ level.
In conclusion, the incorporation of an intra-day variability model of insulin
sensitivity parameters into the UVA/Padova T1DM simulator has allowed ex-
tending its domain of validity from a single-meal time-invariant to a multiple-
meal time-varying scenario, making the simulator suitable to perform longer
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realistic in silico trials. However, further improvements in this direction will
be required to completely describe the glucose variability in the long-term.
It would be certainly of interest to investigate the SI variations in a longer
scenario (e.g. exploiting the data provided by the recent monthly study in
T1DM [53]). In this regard, the method to estimate SI with the oral min-
imal model is unsuitable because of the availability of only CGM and insulin
pump data. However, a recently proposed method for the estimation of SI in
T1DM subjects from CGM and insulin pump data [80] could be used, thus
allowing a model reﬁnement in the near future.
The proposed model of intra-day variability of insulin sensitivity with
the results provided above, have been published in [96].
7
Employment of the T1DM simulator
7.1 Introduction
In this chapter, the application of the UVA/Padova T1DM simulator in
two case studies is presented. In particular, a new adaptive artiﬁcial pancreas
controller is described, in which the simulator served to the in silico testing
of the control performance in one month. Then, a second example is shown,
in which a pharmacokinetic model of an inhaled insulin is developed and
incorporated into the simulator, in order to evaluate in silico the eﬀects of
several dosing regimens.
7.2 In silico testing of adaptive artiﬁcial pan-
creas control algorithms
As already discussed in Chapter 1.1.2, in the past decade the research
has seen unprecedented advances in AP technology, which moved from short-
term inpatient studies to short trials at home employing wireless, portable,
wearable AP systems. Several studies were conducted in adults, e.g. those
using an AP system based on a Modular Model Predictive Control algorithm
(MMPC) [70, 85, 90], in gradually less structured and less monitored settings:
inpatient ﬁrst [7], 2-day in hotel settings [26, 27], and, recently, 2-month
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evening & night at home [53]. The formerly conducted studies had a limited
duration and were restricted to evening and night, thus allowing to neglect
the impact of intra- and inter-day glucose response variability of each subject,
e.g. to insulin and meals. The latter is a well-known phenomenon and became
a major issue with the introduction of longer (week/month) home trials. This
large subject-speciﬁc variability calls for an adaptive controller. To reliably
test such controller in silico, a time-varying simulator is needed, and thus
motivated the developement presented in Chapter 6.
In the following section, an adaptive AP MMPC algorithm based on the
Run-to-Run (R2R) approach is described in summary. The R2R is a well-
known learning-type control algorithm [98] that learns information about
the control quality from the current run and changes the control variable to
apply in the next run. The R2R strategy has already been used for glucose
control in T1DM subjects on the basis of a few daily self-monitoring blood
glucose (SMBG) measurements [6669, 104] or using CGM data [33, 89, 92]
to adapt day-by-day basal insulin delivery or the insulin meal bolus. R2R
in the AP context was introduced in [59], where the aggressiveness of the
controller was adapted by using the maximum and minimum glucose values
provided by CGM.
In this example, it is described a much more realistic R2R approach for
tuning the MMPC algorithm which adapts the basal insulin delivery during
the night and the CR during the day, and its in silico test using the new
time-varying UVA/Padova T1DM simulator.
7.2.1 Run-to-Run strategy for adaptive MPC tuning
The MMPC algorithm considered here is the linear model predictive
control described in [90]. The principal parameters used for control tun-
ing and individualization are the basal insulin delivery, the CR, the CF and
the body weight (BW). In particular, the MMPC computes an insulin vari-
ation with respect to the basal proﬁle, uses CR and CF (taking into account
also the insulin on board, i.e. the amount of insulin, coming from previous
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bolus/infusions, that is still active in the body) to compute the insulin refer-
ence in the cost function, and BW and CR to tune the control aggressiveness.
Thus, the adaptive MMPC aims to: (i) optimize the tuning of the controller
parameters; (ii) adapt them to the inter-day variability. Speciﬁcally, the R2R
strategy is applied to update both the basal insulin delivery and CR para-
meter (and thus the meal insulin bolus); the update is applied in the next
day (run) on the basis of the performance measured during the previous day
(run). The choice of the performance indices is a critical point for the suc-
cess of the R2R. CGM sensors (usually employed in an AP context) allow
including clinically relevant indices into the problem, e.g. the percentage of
time spent in hypo-, eu-, and hyper-glycemic range, and the average blood
glucose (BG). In particular, since a major concern in T1DM therapy is to
avoid hypoglycemia, the updating law is primarily designed to lead to 0 the
percentage of time spent in hypoglycemia (i.e. BG < 70 mg/dL). Once this
primary goal is achieved, a secondary updating law is designed to reduce the
percentage of time spent above 180 mg/dL and to lead the average BG to
the desired target.
For each run, the variation of the basal insulin rate is proportional to the
applied basal delivery and to the performance indices computed during the
previous run. In order to give priority in avoiding hypoglycemia, a switch-
ing condition depending on the percentage of time spent below 70 mg/dL is
introduced. In particular, at run k, the updating law is deﬁned as follows:
b(k + 1) =

b(k)− b¯kb1T bb (k) if T bb (k) > 0
b(k) + b¯
(
kb2T
b
a(k) + k
b
3·
Gbm(k)−GbT
GbT
)
if T bb (k) = 0
(7.1)
where b is the basal insulin delivery, the constants kb1, k
b
2, k
b
3 are the R2R
gains, GbT is the glycemic target, b¯ is the initial basal therapy, and T
b
b , T
b
a ,
Gbm are the R2R performance indices associated with the night interval. In
particular, T bb is the percentage of time spent below 70 mg/dL, T
b
a is the
percentage of time spent above 180 mg/dL, and Gbm is the average glucose
concentration in the evaluation interval, which is equal to the night interval
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delayed by 3 hours.
A similar updating law is used to optimize the CR values, which are assumed
to be constant along n daily intervals [tBj ; t
B
j+1], j = 1, ..., n, with t
B
n+1 = t
B
1 .
In particular, at run k, the updating law for the jth interval is deﬁned as
follows:
Bj(k + 1) =

Bj(k)− B¯jkB1 TBjb (k) if TBjb (k) > 0
Bj(k) + B¯j
(
kB2 T
Bj
a (k) + kB3 ·
G
Bj
m (k)−GBT
GBT
)
if TBjb (k) = 0
(7.2)
where Bj(k) = 1/CRj(k) is the inverse of the CR at run k during the interval
j, the constants kB1 , k
B
2 , k
B
3 are the R2R gains, G
B
T is the glycemic target,
constant for all the intervals, B¯j = Bj(0) is the initial value in the interval
j, and TBjb , T
Bj
a , G
Bj
m are the R2R performance indices associated with the j
interval. In particular, TBjb is the percentage of time spent below 70 mg/dL,
T
Bj
a is the percentage of time spent above 180 mg/dL, and G
Bj
m is the average
glucose concentration collected in the jth evaluation interval. The maximum
length of each jth evaluation interval is 7h; it starts from the meal time in
the jth interval and is truncated if another meal occurs.
The stability of the proposed strategy can be demonstrated by applying the
method described in [89], where a R2R approach for adapting a piecewise
basal therapy in an open-loop context is proposed. A key assumption is that
disjoint intervals are used to update basal insulin or CR: this is an important
requirement, otherwise the problem would move from several scalar to a
multivariable framework, with a signiﬁcant increase of complexity both in
terms of algorithm tuning and stability analysis.
7.2.2 In silico testing
The R2R algorithm described above has been tested on the 100 in silico
adults of the simulator incorporating the SI intra-day variability model de-
scribed in Chapter 6. A model of CGM sensor error noise, described in [90],
is included.
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The night interval considered for basal insulin update is [0:00 am; 8:00 am]
for all the patients. The n (n = 3) time intervals deﬁning the piecewise con-
stant CR are bounded by tB1 = 8:00 am, t
B
2 = 1:00 pm, t
B
3 = 8:00 pm for all
the patients. R2R gains are ﬁxed to kb1 = 0.15, k
b
2 = 0.175, k
b
3 = 0.005, and
GbT = 115 mg/dL, for the basal and to k
B
1 = 0.3, k
B
2 = 0.05, k
B
3 = 0.01, and
GBT = 115 mg/dL, for CR update.
One-month scenario is simulated (more precisely 29 days), in which three
meals per day are administered at 8:00 am, 1:00 pm, and 8:00 pm having 40
g, 80 g, and 60 g of CHO, respectively. Moreover, if the BG falls below 65
mg/dL, the protocol prescribes a rescue CHO dose of 16 g (hypotreatment).
Two hypotreatments are separated by at least 30 minutes. The simulations
are performed twice, either by using the MMPC strategy described in [90]
(CL) or by employing the adaptive MMPC enhanced by the R2R strategy
(CLR2R).
Performance metrics include average (A) BG and standard deviation (SD),
percentage of time spent in euglycemic target range [70-180] mg/dL (Tr), per-
centage of time spent above 180 mg/dL (Ta), and percentage of time spent
below 70 mg/dL (Tb).
The performance of CL and CLR2R is also evaluated by using the Control
Variability Grid Analysis (CVGA) [60, 85], which associates the control per-
formance of each in silico subject to a point into a plane. In particular, the
plane is divided in four regions, reﬂecting the control quality and graded
from A (good control) to D (bad control), and the point coordinates (x, y)
represent the minimum and maximum BG values reached by the in silico
subject during the day under analysis.
7.2.3 Results
The average ± SD of simulated BG after one day (Day 2), two weeks
(Day 15) and four weeks (Day 29) are shown in Figure 7.1, left panels : the
postprandial overshoots detected after lunch and dinner (Figure 7.1a) are
considerably reduced after two weeks of R2R (Day 15, Figure 7.1b). A further
reduction is achieved after four weeks (Day 29, Figure 7.1c), also with a
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reduced BG variability. The CVGA plots (Figure 7.1, right panels) also
conﬁrm the CLR2R improvement, by better populating the center of A and
B zones.
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Figure 7.1: Left panels: Comparison of average ± SD glucose time courses in CL
(blue) vs. CLR2R (magenta) on Day 2 (a), Day 15 (b) and Day 29 (c), respectively.
Right panels: CVGA of CL (blue square) vs. CLR2R (magenta circle) on Day 2
(d), Day 15 (e) and Day 29 (f). Each point represents the coordinates (x is the
minimum and y is the maximum glucose values) associated to a single subject.
Numerical comparison of CL vs. CLR2R on the whole experiment duration
is reported in Table 7.1, where the improvement shown by CLR2R is evident.
Performance indices show that the improvement of CLR2R vs. CL is modest
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after one day; after two weeks (Day 15), the improvements in time in range,
time in tight range and time above 180 mg/dL are very much improved
with respect to Day 2. This performance is maintained until the end of the
experiment (Day 29).
Table 7.1: Performance Metrics Improvements
Day 2 Day 15 Day 29
M (mg/dL) 0.26% 3.54% 5.87%
Tt (%) -0.03% 5.82% 5.96%
Ttt (%) 0.45% 11.74% 18.62%
Ta (%) -0.87% -32.62% -39.22%
Percent improvements obtained using the CLR2R algorithm with respect
to the sole CL.
7.2.4 Conclusions
In this section, it has been illustrated the use of the time-varying simu-
lator in order to provide a suitable framework to in silico test the performance
of an adaptive AP algorithm, i.e. the MMPC based on R2R approach, which
uses the percentage of time spent below 70 mg/dL, the percentage of time
spent above 180 mg/dL, and the distance of average glucose from a target to
adapt the basal insulin delivery during the night and the CR during the day.
The encouraging results achieved in silico in a realistic one-month scenario
open to an in vivo testing phase, with potential beneﬁts for T1DM subjects.
7.3 Evaluating the pharmacological eﬀects of
new insulin molecules
As stated in Chapter 1.1.2, the current T1DM therapy (including AP)
uses the subcutaneous route for insulin delivery [16]. Indeed, insulin de-
livered subcutaneously is well-accepted as state of the art, but important
limitations, such as delay and variability in insulin absorption represent the
major challenges, especially in handling post-prandial glucose excursions.
The research on more rapidly absorbed subcutaneous insulin analogs and
76 Employment of the T1DM simulator
other routes of delivery, e.g. pulmonary administration, is very active. The
UVA/Padova T1DM simulator can be used, beyond AP, also to test new
insulin analogs/molecules. In particular, the in silico testing may help an
eﬃcient design of clinical trials.
In this section, an example of in silico testing of a recombinant human
insulin is presented: the novel ultra-rapid TechnosphereR© Insulin (TI) inhal-
ation powder (AfrezzaR©), which has been approved by U.S. FDA to control
high blood glucose in adults with type 1 and type 2 diabetes. AfrezzaR© is a
dry powder formulation of recombinant human insulin administered by pul-
monary route directly before the meal using a new drug delivery system. It is
characterized by fast absorption (with a peak serum concentration achieved
in about 15 minutes) and short duration of action (2-3 h) due to a short half-
life [6]. This fast absorption of insulin can overcome the delay inherent to the
current subcutaneously injected insulin analogs, but opens new challenges to
cope with the duration of post-prandial glucose elevation, which might take
from 4 to 6 hours to return to pre-meal values. Thus, alternative regimens
are being explored, such as post-meal dosing or split doses (e.g. pre- and
post-meal), which could achieve optimal post-prandial glucose control.
Here, a system pharmacology modeling approach is used. In particular, a
recently proposed version of the T1DM simulator incorporating a pharma-
cokinetic (PK) model of TI insulin [97] is used to simulate post-prandial
glucose response in T1DM patients treated with TI administered at diﬀerent
times (e.g. before the meal or within the meal period), or in diﬀerent fashions
(e.g. split dosage rather than a single bolus).
This study has been conducted in collaboration with Sanoﬁ US, Inc.,
under the supervision of Dr. Thomas Klabunde.
7.3.1 T1DM simulator incorporating inhaled insulin PK
To describe pharmacokinetic/pharmacodynamic (PK/PD) of AfrezzaR©
observed in T1DM subjects, a PK model of TI insulin has been developed and
identiﬁed on a T1DM population treated with AfrezzaR© [9]. In particular,
the PK model is a variation of the single-compartment model described by
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Potocka in [74]:
I˙TI(t) = −kaTI ·ITI(t) + FTI ·D ITI = 0 (7.3)
where ITI is the amount of insulin in the alveolar space, D (pmol/kg/min) is
the TI dose, FTI is the fraction of inhaled insulin which actually appears in
plasma, and kaTI (min−1) is the rate constant of pulmonary insulin absorp-
tion.
The model of T1DM simulator has been properly modiﬁed (Figure 7.2): in
particular, model equations are the same of those reported in Chapter 2.2.1,
except for the rate of appearance of external insulin in plasma (RaI), which
takes into account TI contribution
RaI(t) = ka1·Isc1(t) + ka2·Isc2(t) + kaTI ·ITI(t) (7.4)
where kaTI and ITI(t) are those appearing in equation (7.3). Individual PK
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Figure 7.2: Scheme of the T1DM simulator incorporating the PK model of
AfrezzaR©.
parameters of TI insulin have been generated paralleling what is described in
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Chapter 2.3.3, i.e. they were randomly extracted from the joint parameter
distribution that has been created using the parameter estimates obtained
from model identiﬁcation on insulin data of T1DM subjects [9]. Then, each
individual PK has been randomly assigned to each in silico subject. The
T1DM simulator incorporating the PK model has been thus tested in terms
of ability to predict the meal response observed in clinical data: by replicating
in silico the same experimental protocol of [9], it is possible to appreciate how
well the simulated glucose dynamics reﬂected the data (Figure 7.3).
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Figure 7.3: Over-basal glucose and insulin data of [9] (left panels) and simulations
obtained by replicating the same protocol (right panels). At t = 0, subjects received
a meal containing 50g of CHO and an individualized TI dose was given at the same
time; in particular, the TI dose was calculated as a function of the ingested CHO
and the subject's CR. Individual proﬁles are shown, with averages plotted as thick
red lines.
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7.3.2 Simulation scenario
The eﬀect of diﬀerent dosing regimens of AfrezzaR© on post-prandial glu-
cose after a meal test has been explored in 100 virtual patients for pre-meal
and post-meal dosing as well as for split dosing scenarios. In particular, a
meal test with 50 g CHO has been simulated, with AfrezzaR© doses ranging
from 10 to 80 TI Units, with timing ranging from 0 to 120 min after meal,
as illustrated in Figure 7.4.
For all the simulations, the expected risk (e.g. number of expected hypogly-
cemic events) and beneﬁt (e.g. mean plasma glucose of meal test) were
evaluated. To select the most suitable dose for each virtual patient, a ti-
tration rule has been followed, based on the glucose level at 90 min after
meal ingestion (BG90′): if BG90′ is between 110 − 160 mg/dL, TI dose is
considered as adequate; if BG90′ > 160 mg/dL, TI dose has to be increased;
if BG90′ < 110 mg/dL, TI dose has to be decreased.
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Figure 7.4: Scheme of diﬀerent dosing regimens explored in simulation: pre-meal
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7.3.3 Results
Simulations of diﬀerent dosing regimens are shown in Figure 7.5 for one
illustrative in silico subject (VP#004).
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Figure 7.5: Meal experiments in one illustrative in silico subject (VP#004). Up-
per panels: insulin (left) and glucose (right) in response to pre-meal administration
of eight diﬀerent dosages, indicated with diﬀerent colors. Middle panels: insulin
(left) and glucose (right) in response to post-meal dosing (green lines) compared
to pre-meal dosing (blue lines). Lower panels: insulin (left) and glucose (right) in
response to split dosing (green lines) compared to pre-meal dosing (blue lines).
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The eﬀect of inhaled insulin on post-prandial glucose excursion depends on
dose: too low doses lead to suboptimal control of post-prandial glucose; on
the other hand, due to fast appearance of AfrezzaR©, too high pre-meal doses
lead to sharp glucose decline and risk of early hypoglycemic events (Fig-
ure 7.5, upper panel). A ﬂatter proﬁle can be obtained by giving the dose
after meal (Figure 7.5, middle panel) or by splitting the insulin amount in
two doses, one directly before the meal and one after a certain time interval
(Figure 7.5, lower panel). In these cases, higher total doses may be selected
gaining additional eﬃcacy on post-prandial glucose control, without indu-
cing hypoglycemia. Numerical results of this analysis are reported in detail
in Table 7.2, which reports, for each dosing pattern, both the optimal in-
sulin dose satisfying the titration rule and the highest dose not leading to
hypoglycemia.
Table 7.2: Optimal meal dosing in subject VP#004
TI dose BG4hr BG<70mg/dL Optimal dose Highest dose with
(U) (mg/dL) (Y/N) by titration rule no BG<70mg/dL
Pre-meal dosing
10 177.1 N 
20 133.2 N †
30 85.2 Y
Post-meal dosing
10 181.1 N
20 143.2 N 
30 113.2 N †
Split dosing
10-10 139.0 N 
10-20 104.0 N
20-10 91.9 N †
For each insulin dose administered (TI dose, second column), the glucose value
obtained 4 hours after meal (BG4hr, second column) and whether hypoglycemia
occurs (BG<70 mg/dL, third column) are reported. Moreover, for each dosing
pattern (i.e. pre-meal, post-meal, split) both the optimal insulin dose satisfying
the titration rule ( in fourth column) and the highest dose not leading to
hypoglycemia († in ﬁfth column) are indicated.
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7.3.4 Conclusions
In this section, the T1DM simulator was used to model prandial response
to a novel inhaled insulin powder, i.e. the ultrafast-acting TechnosphereR©
Insulin (TI) inhalation powder (AfrezzaR©). In particular, a total of more
than 20,000 simulations of in silico meal tests have been performed in 100
virtual patients to explore the eﬀect of diﬀerent doses and dosing regimens of
AfrezzaR©. The in silico clinical trials are being used to inform the design of
clinical studies evaluating diﬀerent proposed treatment regimens of AfrezzaR©
in T1DM subjects.
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Conclusions
Simulation environments are extremely useful in the type 1 diabetes
(T1DM) research ﬁeld, since they allow to in silico test diﬀerent T1DM treat-
ments (including AP control algorithms) under several experimental condi-
tions.
The focus of the present work is on the University of Virginia (UVA)
and Padova T1DM Simulator [43], a new generation simulator based on
a rather complex model of glucose dynamics and equipped with an in silico
population of 100 adults, 100 adolescents, and 100 children, which is able to
reproduce the inter-subject variability of glucose dynamics in a T1DM popu-
lation. Thanks to this peculiarity, in the 2008 the US Food and Drug Admin-
istration accepted the T1DM simulator (S2008) as a substitute for preclinical
trials for certain insulin treatments, including closed-loop algorithms. This
dramatically accelerated the process for the approval of human trial. The
simulator has been updated in 2013 in order to better describe the distribu-
tion of glucose concentration observed in clinical trials (S2013). However, at
the beginning of this project, the simulator validity was not been assessed
against T1DM clinical data: in fact, at the time of simulator conception, its
model was identifed on a data set of 204 healthy subjects [3], i.e. the sole
including not only plasma glucose and insulin measurements but also estim-
ates of glucose ﬂuxes, required to completely identify all the single processes
of the model. Moreover, the domain of validity of the simulator was limited
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to a single-meal scenario, making the simulator not fully adequate for the in
silico testing of the latest AP algorithms, which aim to glucose control in the
long-term.
The aim of this thesis was thus to overcome these limitations. To do
so, ﬁrst the simulator validity has been clinically assessed using T1DM data
of the now available clinical trials. Then, the model of the simulator has
been validated on a multiple-meal scenario, in order to establish the features
required to extend the domain of validity of the simulator. A model of di-
urnal intra-subject variability of insulin sensitivity has been developed and
incorporated into the simulator, thus making it suitable for long-term clinical
trials. Finally, the use of the simulator has been presented in two illustrative
cases, including setting up a paradigm for in silico testing of pharmacokin-
etics/pharmacodynamics.
For the clinical assessment of the simulator, a T1DM population has been
considered [44], in which 24 T1DM subjects received dinner and breakfast
in two occasions, for a total of 96 postprandial glucose traces. Measured
plasma glucose proﬁles have been compared with those obtained with both
S2013 and S2008, by replicating in 100 in silico adults the same experimental
condition of the data, i.e. the same meal amount, insulin bolus and basal
delivery. In particular, a matching criterion has been applied: among the
100 in silico subjects, the one behaving similarly to the real patient from
a clinical point of view, i.e. showing similar pattern and lying in the same
clinically relevant zones (i.e. hypo-, eu-, hyper-glycemia), has been selected
as best match, based on a performance index (FIT) that quantify the agree-
ment between real and virtual glucose trace. Then, the glucose trace of the
vitual match has been assessed against the data using the continuous glucose
error grid analysis (CG-EGA).
The results have highlighted the improvement achieved with S2013 with re-
spect to S2008, particularly in hypoglycemia, where the percentage of ac-
curacy was more than doubled (from 40.7% to 85.9%), thus well reﬂecting
the frequency of hypoglycemic episodes observed experimentally. In addi-
tion, the distribution of the most common outcome metrics obtained with
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S2013 was very similar to those obtained experimentally. These results have
demonstrated that the in silico adults of the S2013 are representative of the
same age T1DM population observed in a clinical trial, thus proving that the
S2013 is a valid tool usable to test the robustness of AP closed loop control
algorithms. However, this procedure did not provide any information about
the goodness of the model or the adequacy of the joint parameter distribution
included into the simulator. Moreover, two diﬀerent in silico subjects have
been required to well match the post-dinner and post-breakfast glucose traces
of the same real subject, suggesting that intra-subject variability, e.g. due
to meals or circadian rithms, should be taken into account to well describe
blood glucose in a longer scenario, beyond the single meal.
The T1DM model has been thus validated using data coming from a large
multicenter AP clinical trial [58], consisting of 47 T1DM subjects receiving
dinner (D), breakfast (B) and lunch (L) in three admissions, for a total of 23
hours per session, for which only plasma glucose and insulin measurements
were available. To cope with the lack of glucose ﬂuxes − which are available
only if complex experiments with multiple tracers are used − a Bayesian
approach has been adopted for the T1DM model identiﬁcation; in particu-
lar, the Maximum a Posteriori (MAP) estimator has been employed, and the
model parameter joint distribution included into the simulator has been used
as a priori information. Variability of model parameters describing glucose
absorption has been allowed among B, L, and D, in order to describe possible
diﬀerences in meal compositions. Moreover, also variability of parameter de-
scribing insulin sensitivity (SI), i.e. the ability of insulin to stimulate glucose
disposal and inhibit glucose production, has been permitted, based on the
notion that T1DM subjects exhibit, on average, a SI trend lower at B com-
pared to L and D [34].
The results of model identiﬁcation were satisfactory: the model well ﬁtted
the glucose data, providing a very good coeﬃcient of determination (R2 =
0.962 ± 0.027) and precision of parameter estimates (CV = 1.3% ± 0.2%).
Absorption parameters at B were signiﬁcantly diﬀerent (P < 0.0001) from
those at L and D, reﬂecting more rapid dynamics of glucose absorption likely
due to the diﬀerent compositions; on the other hand, SI parameters were
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not statistically signiﬁcant, agreeing with that found in [34]. To evaluate
the adequacy of the a priori distribution used in the identiﬁcation process,
an iterative two-stage approach has been employed: in this regard, the re-
lative diﬀerences in model parameters were modest, getting lower than 5%
already after the second iteration. In addition, the posterior distributions
were statistically identical among the iterations, except for some of the ab-
sorption parameters: however, this result was in some sense expected, since
the meal composition in the employed data (solid meal) diﬀers from that
used for generating the simulator prior (Jell-O meal [3]). Thus, with the pro-
posed Bayesian approach, the adequacy of the joint parameter distribution
included into the simulator has been demonstrated. Moreover, the diﬀerences
found in glucose absorption and SI parameters proved that the incorporation
of a model of diurnal variability of some parameters is a prerequisite to make
the simulator able to describe glucose on a multiple-meal scenario. However,
it is worth noting that, due to the small amount of samples collected after
lunch, at variance with [34], here SI parameters at L and D were assumed
to be equal in each subject. This was necessary to guarantee that model
parameters at L were estimated with good precision.
Therefore, to assess intra-day variability of SI parameters a diﬀerent data-
set had to be considered, also to avoid the possible confoundung eﬀect in-
troduced by diﬀerent compositions and carbs contents of the meal. The
assessment of daily variation of insulin sensitivity has been thus tackeled
considering data of 20 T1DM subjects undergoing a triple-tracer mixed-meal
study protocol [4] during B, L, or D in a randomized Latin square design.
Then, meal composition were the same among B, L and D: by doing so, the
diurnal pattern of SI (estimated from plasma glucose and insulin data with
the oral minimal model [13]) was not aﬀected by any other possible confound-
ing eﬀects. In particular, it was found that, on average, SI was lower at B
with respect to L and D, but without showing a signiﬁcant diurnal pattern,
both due to the small population size and the high inter-subject variability.
Thus, the idea presented in this work was to classify each subject based on
his SI diurnal pattern, and then to incorporate this information into the sim-
ulator. Seven possible daily patterns of SI have been identiﬁed, and their
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probabilities have been estimated from the data. Each in silico subject in-
cluded into the simulator was then associated to one of the seven variabil-
ity patterns, and its insulin sensitivity parameters, i.e. Vmx and kp3, have
been made time-varying, according to the speciﬁc SI pattern. Consequently,
for each in silico subject, three values of carbohydrate-to-insulin ratio (CR,
determining the amount of insulin required to cover a meal) have been cal-
culated for B, L and D, respectively. To test the goodness of the model,
the same experimental protocol of the data has been replicated in silico :
the comparison of simulated glucose traces against the data was satisfactory,
showing the same behavior observed in the data, i.e. higher glucose level at
B with respect to L and D, and, furthermore, well capturing the variability
of the data in all the post-prandial portions.
Hence, incorporating the model of intra-day insulin sensitivity into the T1DM
simulator allowed extending its domain of validity to a multiple-meal scen-
ario, thus allowing a more robust AP testing in the long-term.
Finally, two case studies of application of the simulator have been presen-
ted. First, the simulator incorporating the developed variability model has
been employed for the testing of a new adative AP controller: a Run-to-Run
(R2R) approach has been applied to a model predictive control algorithm,
and in silico tested on a monthly scenario. In particular, the intra-/inter-day
variations in subjects parameters have permitted to highlight the improve-
ment achievable in glucose control by using the R2R approach. In the second
example, the simulator has been used for testing the pharmacological eﬀect
of an inaled insulin. Speciﬁcally, the simulator have served to evaluate the
post-prandial glucose in response to diﬀerent insulin dosing regimens, thus
allowing to determine, for each in silico subject, the best insulin pattern to
optimally control post-prandial glucose.
In conclusion, in this thesis, the UVA/Padova T1DM simulator has been
assessed against T1DM clinical data, proving to be representative of a T1DM
population studied in a clinical trial. Then, the model included into the sim-
ulator has been ﬁtted, for the ﬁrst time, on a large T1DM population studied
in an almost 24-hour period. To do this, a Bayesian approach has been adop-
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ted, since the availability of glucose and insulin data only does not allow the
use of a weighted least squares or maximum likelihood estimator. The chosen
prior was the joint parameter distribution included in the T1DM simulator
for the generation of the in silico subjects. This implicitly has proved the
adequacy of the distribution used in the simulator. In addition, this analysis
has pointed out the need to introduce diurnal variation of some key paramet-
ers, i.e. those related to meal glucose absorption and insulin sensitivity, to
be able to well describe the glucose dynamics in a day. A model of intra-day
variability of insulin sensitivity has been developed, based on an appropriate
dataset, and incorporated into the simulator in order to make it suitable for
the in silico testing of new long-term AP control algorithms. Finally, the new
time-varying T1DM simulator has been employed for the preclinical testing
phase of an adaptive R2R control algorithm and for the evaluation of the
pharmacological eﬀect of a novel inhaled insulin, thus proving to be a useful
tool for the in silico testing of T1DM treatments.
Further studies are needed to improve the description of SI variability
in long-term (beyond the intra-day variability), and also to develop a model
of glucose absorption depending on the meal composition, in order to better
cope with the factors that inﬂuence the glucose variability in the long-term.
Further testing is also needed to apply the Bayesian approach to CGM sensor
and insulin pump data available in clinical experiments.
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